Next Article in Journal
Marine Pyrrolocarbazoles and Analogues: Synthesis and Kinase Inhibition
Next Article in Special Issue
Calyculins and Related Marine Natural Products as Serine- Threonine Protein Phosphatase PP1 and PP2A Inhibitors and Total Syntheses of Calyculin A, B, and C
Previous Article in Journal
The Antinociceptive and Anti-Inflammatory Activities of Caulerpin, a Bisindole Alkaloid Isolated from Seaweeds of the Genus Caulerpa
Previous Article in Special Issue
Total Synthesis and Absolute Configuration of the Marine Norditerpenoid Xestenone
Article Menu

Export Article

Marine Drugs 2009, 7(4), 705-753; doi:10.3390/md7040705

A Submarine Journey: The Pyrrole-Imidazole Alkaloids
Barbara Forte 1, Beatrice Malgesini 2, Claudia Piutti 1, Francesca Quartieri 2, Alessandra Scolaro 1 and Gianluca Papeo 1,*
Department of Medicinal Chemistry, Nerviano Medical Sciences, Viale Pasteur 10, 20014 Nerviano, Milano, Italy
Department of Chemical Core Technologies, Nerviano Medical Sciences, Viale Pasteur 10, 20014 Nerviano, Milano, Italy
Dedicated to our colleague and friend Dr. Sergio Mantegani, in recognition of his merits in natural products chemistry, and in appreciation of his relentless endeavor to teach, advise and share his chemistry skills in our organization.
Author to whom correspondence should be addressed; Tel.: +39-0331-58-1537; Fax: +39-0331-58-1347.
Received: 30 October 2009; in revised form: 20 November 2009 / Accepted: 26 November 2009 / Published: 27 November 2009


In his most celebrated tale “The Picture of Dorian Gray”, Oscar Wilde stated that “those who go beneath the surface do so at their peril”. This sentence could be a prophetical warning for the practitioner who voluntarily challenges himself with trying to synthesize marine sponge-deriving pyrrole-imidazole alkaloids. This now nearly triple-digit membered community has been growing exponentially in the last 20 years, both in terms of new representatives and topological complexity – from simple, achiral oroidin to the breathtaking 12-ring stylissadines A and B, each possessing 16 stereocenters. While the biosynthesis and the role in the sponge economy of most of these alkaloids still lies in the realm of speculations, significant biological activities for some of them have clearly emerged. This review will account for the progress in achieving the total synthesis of the more biologically enticing members of this class of natural products.
pyrrole-imidazole alkaloids; total synthesis; marine sponges; oroidin

1. Introduction

Sometime in 2003, our Company decided to set up a new project based upon the chance of fishing out new potent and selective kinase inhibitors from the natural products armoury. Particularly, the task was to play with the marine-origin metabolite hymenialdisine (see Subsection 3.1), a natural-born pan-kinase inhibitor. The goal of that project would have been to first synthesize this pyrrole-imidazole alkaloid and then to bias its biological activity through chemical manipulations. A non-biomimetic, simple disconnection allowed us to cut off the double bond connecting the northern glycocyamidine ring with the southern pyrroloazepinone, thus envisioning aldisine as the suitable key intermediate. However, as soon as we were able to routinely produce multigram batches of this intermediate, an outstanding paper from Wan et al. [1] (see Subsection 3.1) was published, in which a number of hymenialdisine derivatives, even larger than in our rosiest hopes, was synthesized. Despite this setback, we pursued anyway the opportunity to successfully complete the hymenialdisine synthesis. From then on, the temptation of challenging other pyrrole-imidazole alkaloids was hard to resist, as much as it was hard to resist the enjoyment of the stimulating literature dealing with those natural products, published during the last five years in exponentially growing numbers.
The idea of a review recounting the efforts and achievements in the total synthesis of pyrrole-imidazole alkaloids was actually born from the perusal of these papers. However, as a number of reviews dealing with this topic are already available [210], we decided to cover the literature from 2005 to mid-2009 by focusing only on those alkaloids possessing a clear pharmacological value. A brief discussion on the biogenesis and the ecological role of these natural products will be the hors-d’œuvre.

1.1. Pyrrole-Imidazole Alkaloids Sources and Biogenesis

The pyrrole-imidazole alkaloids (PIAs) family comprises hundreds of secondary metabolites originating from marine sponges exclusively. Those natural products, whose architectural complexity goes from simple, achiral, monomeric oroidin (1, Figure 1) to the breath-taking 16-stereocenter-containing tetrameric stylissadine A and B (2 and 3, Figure 1), have been mainly isolated from various species of Agelasidae, Axinellidae, Dyctionellidae and Hymeniacidonidae families of sponges [2]. The systematic recurrence of PIAs in these families of sponges allowed to speculate their taxon-specificity and then to consider these secondary metabolites as chemical markers for phylogenetically related sponges [11,12]. The localization of those alkaloids in sponge cells has recently been investigated [13].
There are numerous speculations in the literature on the biogenesis of PIAs. As the simple oroidin (1, Figure 1) is mostly considered to be the biogenetic precursor of any other alkaloid pertaining to this family, those hypotheses can be grouped according to their pre- or post- oroidin focus. Pre-oroidin speculations are based on the fundamental aminoacids involved in the production of oroidin in living organisms (Figure 2). Thus, proline and/or ornithine may provide the backbone to build up the pyrrole-2-carboxylic acid moiety, while histidine may contribute to the 2-aminoimidazole portion. Low incorporation of these three aminoacids in the biosynthesis of the oroidin cyclized derivative stevensine has been experimentally observed by Kerr et al. by feeding cell cultures of the marine sponge Axinella corrugata (previously Teichaxinella morchella) with the corresponding 14C-labeled aminoacids [14]. Alternatively, ornithine [11,12] as well as lysine [15] may be the source of the the five contiguous carbon atoms present in the aminopropenylimidazole portion of oroidin. A more recent and intriguing hypothesis emerged upon the isolation of verpacamides A-D (e.g. verpacamide C, 4, Figure 2) from the marine sponge Axinella vaceleti [16].
These cyclo(l-Arg-l-Pro) dipeptides differ only by their oxidative state, thus resembling intermediates along a given biogenetic pathway. The authors, by capitalizing on the discovery of an unprecedented conversion of proline into 2-aminoimidazolone [17], speculate that verpacamides may represent the biogenetic precursors of dispacamide A (5, Figure 2), a postulated forerunner of oroidin.
Post-oroidin hypotheses, on the other hand, can be sub-classified according to the alkaloids and their respective biosynthesis. Thus, along with a number of biochemical considerations on single natural products, frequently formulated while disclosing their isolation [1828], more general speculations that try to link as many PIAs as possible have emerged. The seminal paper in this respect was published in 2001 by Al Mourabit and Potier (A/P) [29]. The ability of a given enzyme, through proton exchange reactions, to govern the tautomeric equilibria (and consequently the corresponding nucleophilic/electrophilic behaviour) of the aminopropenylimidazole portion of oroidin, was hypothesized to be the key point for the formation of both polycyclic monomers and cyclized dimers. The common intermediate (6, Figure 2) arising from oroidin that the authors invoked for the formation of the palau’amines, the styloguanidines and the axinellamines groups of alkaloids (see Section 5), was subsequently elaborated by Köck, Baran et al. (K/B) from both a stereochemical and an oxidative state point of view [30], in light of the recently revised structure of palau’amine (see Section 5). The symmetry that this revision finally brought to the cyclized dimeric members of the PIAs family, allowed the so-called “pre-axinellamines” intermediate (7, Figure 2) not only to more precisely connect the aforementioned groups of natural compounds, but also to include the konbu’acidins and the subsequently isolated massadines and stylissadines in this network. According to the same hypothesis, the “pre-axinellamines” 7 may be derived, in turn, from oroidin (1), sceptrin (8, Figure 2) or from ageliferin (9, Figure 2) [30]. Interestingly, the amide hydrolysis that Köck, Baran et al. invoked in order to cleave redundant bromopyrrole moieties in the styloguanidine and palau'amine biosynthetic hypothesis (see Section 5) [30], is in agreement with the supposition that the 4,5-dibromopyrrole-2-carboxylic acid derives from oroidin hydrolysis, and is not one of its precursors [17].
If, on the one hand, nothing is known about either the enzymes or the corresponding genes by which sponges perform the aforementioned biogenetic transformations, on the other hand, haloperoxidase-mediated introduction of halogen(s) onto those marine alkaloids are easy to be inferred. Those enzymes, whose cofactors are represented by heme iron or vanadium, employ hydrogen peroxide to generate a metal-bound hypohalite ion, that is the electrophilic halogen source responsible for the halogenation of electron-rich substrates like the pyrrole nucleus in PIAs [31,32]. Other, recently discovered, haloperoxidases (e.g., PrnA) use flavin adenine dinucleotide as a metal-free cofactor to halogenate nucleophilic substrates [33].
The absolute configuration of many of the more complex members of the PIAs family is still not known. Despite the fact that tentative assignment through CD spectroscopy (for a recent example, see Nishimura et al. [34]) for some of the simpler representatives has proven to be correct [3537], only total synthesis can tell us which enantiomer is the natural one.

1.2. Pyrrole-Imidazole Alkaloids Ecological Role

PIAs’ ecological role started to be investigated in the late ‘90s, when it was realized that sponges’ structural defences alone (spongin fibers and glass spicules) were ineffective feeding deterrents towards predatory reef fishes. The first report in this respect dates back to 1996, when an ecoassay-guided isolation, performed on the extracts of sponges of the genus Agelas, allowed the identification of 4,5-dibromopyrrole-2-carboxylic acid and oroidin (1) as the major components responsible for the observed chemical feeding deterrence [38]. Later on, stevensine, present in high concentration in the sponge Axinella corrugata (previously Teichaxinella morchella), was also demonstrated to possess antifeedant properties [39]. A structure-activity antifeedant relationship was subsequently established for oroidin-like molecules [40]. From these studies, the imidazole moiety, while not being active per se, looks like an enhancer of the deterrent activity exerted by the pyrrole counterpart. Other PIAs were recognized to chemically defend sponges from predators [41]. Acquarium and field feeding assays unveiled sceptrin (8) as the major metabolite of Agelas conifera able to deter fish feeding at natural concentrations, and it allowed ranking of a number of PIAs according to their antifeedant activities. This work, furthermore, highlighted the experimental observation that a higher number of bromine atoms present in the metabolite correlates with a higher feeding deterrent potency [42]. The ecological role of PIAs has been tentatively explained by a general interaction of those metabolites with the cellular calcium homeostasis [43,44]. From all those information, indicating that PIAs play a defensive role in sponges’ economy, still something is missing in our understanding. Combinations of PIAs did not provide any evidence of synergic activity [40]. Concentrations of some PIAs in the sponges are so low to have negligible deterrent effects [40,42]. Thus, the spontaneous question remains unanswered: “Why do sponges synthesize such a large number of alkaloids?”
Moreover, the isolation of both (+)-dibromophakellin (from Pseudoaxynissa cantharella [45]) and (−)-dibromophakellin (from Phakellia flabellate [25]) as well as (+)-dibromoisophakellin (from Pseudoaxynissa cantharella [45]) and (−)-dibromoisophakellin (from Acanthella carteri [46]) further complicates the scenario. As evolutionary pressure should select which enantiomer is better to perform a given function, do these enantiomeric alkaloids have a different ecological role in the biology of the sponge?

1.3. Pyrrole-Imidazole Alkaloids Classification

The 2-amino-4(5)-vinylimidazole portion of PIAs can vary with regard to its oxidative as well as hydration state, while the pyrrole-carboxamide moiety structural variations reside exclusively in the absence or the presence of bromine atom(s) in 2- and/or 3- position(s) of the pyrrole nucleus. The most commonly accepted PIA classification [2,9] is based upon both the number of “oroidin units” and the presence of extra-rings involving either the imidazole or the pyrrole portion of the alkaloids. Accordingly, five classes of PIAs will be encountered in the following sections:
  • Acyclic monomers
  • Cyclic monomers
  • Acyclic dimers
  • Cyclic dimers
  • Cyclic tetramers
Alkaloids whose structures hardly fit any of the aforementioned classification criteria have been included in a sixth additional class.

2. Acyclic Monomers

2.1. Oroidin

Oroidin (1) was isolated in 1971 from the marine sponge Agelas oroides [47]. It is the simplest among bromopyrrole-imidazole alkaloids and it has a linear structure characterized by a bromopyrrole carboxamide and an amino-imidazole moiety linked through a propenyl chain. Oroidin is the most abundant PIA and, as already mentioned (Subsection 1.1), it might be considered a biogenetic precursor of the other alkaloids.
Efforts towards the synthesis of oroidin followed two main strategies [2] employing either an already assembled imidazole ring [4850] or an open chain precursor of imidazole [51,52]. In 2006, two total syntheses of oroidin were published, and both works have been recently reviewed [10].
Ando et al. [53] described a method involving a versatile intermediate 10, arising from 2-aminoimidazol-4-carbaldehyde, that allowed the synthesis not only of oroidin (1) and hymenidin (11), but also dispacamide A (5) and dispacamide B (12). The general approach of the synthesis is reported in Scheme 1, while in Subsection 2.2 a full detailed version is described for the dispacamides.
Al Mourabit et al. [54], inspired by the natural product dibromoagelaspongine [19], performed a one-pot bromine-mediated oxidative addition of 2-aminopyrimidine, as a masked guanidine, on N-acyl-1,2-dihydropyridine 13. The synthesis proved to be short and exquisite, with only little mass loss and good final yields (Scheme 2).
The function of oroidin (1) as chemical defense for sponges of the genus Agelas against predation by the reef fish Thalassomia bifasciatum has already been mentioned (see subsection 1.2). Besides, 1 inhibits larval metamorphosis of the barnacle Balanus amphitrite (ED50 = 15 μg/mL) [21]. Oroidin was also reported to possess antibiofilm activity against the marine α-proteobacteria R. salexigens [55] and the medically relevant γ-proteobacterium Pseudomonas aeruginosa (PA; IC50 = 190 μM on PA01; IC50 = 166 μM on PA14) [56]. With the aim of finding new chemical entities able to inhibit the formation of bacterial biofilms [5759], the simple and linear oroidin was proposed as a lead compound for SAR studies. Melander’s group synthesized several libraries of analogues based upon the oroidin template and the 2-aminoimidazole moiety (Figure 3).
Reverse amides [60,61], N-pyrrole substitutions [62], amide isosters [63] and linker modifications [64] are only few examples of a huge and successful synthetic work that led to the discovery of small molecules able to inhibit and disperse biofilms across order, class and phylum.

2.2. Dispacamide A

In dispacamide A (5), isolated in 1996 by Fattorusso et al. [65] from the sponge Agelas dispar, the oroidin 2-aminoimidazole moiety is oxidized to an alkylidene glycocyamidine. Dispacamide A is a potent, non competitive, antihistaminic agent, showing activity in the micromolar range on the guinea pig ileum [36,65] (pD2 5.52 ± 0.11, where pD2 is the negative logarithm of the molar concentrations of the antagonists which induced a 50% decrease in the maximal response to the agonist). It also shows fish feeding deterrence (10 mM) [40].
Length and functionalization of the central linear chain are crucial parameters for the antihistaminic activity, whereas the presence of a bromine atom at position 2 of the pyrrole ring is not relevant. From a biogenetic point of view, dispacamide A is assumed [66] to be the direct precursor of pyrroloazepinone hymenialdisine (see Subsection 3.1).
Several total syntheses of dispacamide A have hitherto been reported [51,66,67] and reviewed [4], in particular by Lindel et al. [2]. More recently, Ando et al. published a novel approach, which is described in Scheme 3 and was already mentioned in the oroidin subsection (see Scheme 1) [53]. In Ando’s strategy, the pyrrole part of the congeners for natural 2-aminoimidazole alkaloids was introduced at a later stage of the synthesis.
3-Bromo-1,1-dimethoxypropan-2-one and tert-butoxy-carbonylguanidine produced the functionalized aminoimidazole ring 14 in acceptable yield, which was then manipulated to furnish the suitably protected key intermediate 1,2-bis-tert-butoxycarbonylaminoimidazol-4-carbaldehyde (10).
The two building blocks 10 and 15 were then coupled via Julia olefination thus providing E olefin 16 in good yield and good selectivity. From 16, the syntheses of oroidin (1) and hymenidin (11) were achieved (steps not shown), while hydrogenating the double bond paved the way for the preparation of dispacamides A (5) and B (12). The imidazole nucleus was oxidized with tetra-n-butylammonium tribromide and the primary amino group needed to be selectively Boc-protected for ease of purification. Final amidation with trichloroacetyl-pyrroles led to the desired dispacamides and could be used (in principle) to readily prepare derivatives with structural motifs differing from those involved in the natural products.

3. Cyclic Monomers

3.1. Hymenialdisine

(Z)-Hymenialdisine [(Z)-HMD; 17, Figure 4] is the only PIA potently active as kinase inhibitor. As it showed nanomolar kinase inhibitory activity against a wide panel of kinases [68], it is potentially useful not only for the treatment of cancer, but also for illnesses such as Alzheimer’s disease and type 2 diabetes.
Nguyen and Tepe [69] recently published a review offering an exhaustive overview on several aspects of these molecules. (Z)-HMD (17) was originally isolated from marine sponges of the genera Hymeniacidon, Acanthella, Axinella, and Pseudoaxinyssa, while (Z)-2-debromohymenialdisine (DBH) (19) came from the sponge Phakellia [70].
(Z)-Hymenialdisines differ only by the presence of a bromine atom in the pyrrole α-position; these compounds share a fused bicyclic pyrrole[2,3-c]azepin-8-one linked through a double bond with a glycocyamidine ring. A few groups contributed to characterize HMD and DBH with spectral and X-ray studies [11,71,72].
Both the (E) and (Z) isomers have been isolated; they interconvert in a pH- and concentration-dependent manner [73] and (Z)-HMD (17) is the most abundant one, due to its higher thermodynamical stability.
Synthetic approaches [7478] towards (Z)-HMD (17) and (Z)-DBH (19) have been reported (Scheme 4). 1-Benzoyl-2-methylsulfanyl-1,5-dihydroimidazol-4-one (21) employed in Papeo’s approach was also useful in the first total synthesis of (Z)-axinohydantoin (see Subsection 3.2).
Initially (Z)-HMD (17) was found to be slightly cytotoxic in PV4 cells (32.5% at 100 μg/ml) [79]. Meijer et al. extensively studied 17 from a structural and biological point of view [68]. (Z)-HMD was found to be a competitive inhibitor of ATP (Ki = 50 nM) and it proved to be a potent inhibitor of kinases like Cyclin-Dependent Kinases, Glycogen Synthase-3β and Casein Kinase 1 (Table 1).
The structure of a CDK2-HMD complex was determined at 2.1 Å resolution, indicating the binding of 17 in the ATP binding pocket [68]. The N1 atom of the pyrrole ring, the carbonyl oxygen and the amide nitrogen of the azepine ring form three hydrogen bonds with Glu81 and Leu83 of the CDK2 backbone. The pyrroloazepine bicyclic core is held in a shallow hydrophobic pocket by several van der Waals contacts with side chain atoms (31 of total 45). The bromine is partially exposed to the solvent and also packed against a few main-chain residues. In addition, the free NH2 group is involved in direct hydrogen bond formation with Asp145, while the glycocyamidine ring system makes other Van der Waals interactions together with two water-mediated hydrogen bonds with the main chain.
In spite of this high in vitro activity, 17 did not show significant inhibition in cells: only 40% of growth inhibition was reached at 100 μM in adenocarcinoma cells [1]. This behaviour might be ascribed to the low permeability of the molecule.
However, being potent pan-kinase inhibitors, HMD and analogues represent a potential for the treatment of neurodegenerative disorders, inflammatory pathologies, diabetes and cancer. Different series of HMD analogues were synthesized in order to establish a SAR [1,80,81]. In those derivatives, the main features that allow (Z)-HMD to bind in the kinase ATP binding site were left unchanged, while attempts have been performed in order to improve selectivity and permeability [8284].

3.2. Axinohydantoins

(E)-Axinohydantoin (23) and (E)-debromoaxinohydantoin (25) were isolated from the sponges Axinella sp. [85] and Monanchora, respectively (genera Hymeniacidon) (Figure 5) [86]. (Z)-Axinohydantoin (22) and (Z)-debromoaxinohydantoin (24) were subsequently isolated from the sponge Stylotella aurantium [87]. Those latter secondary metabolites were also found in Hymeniacidon species (Figure 5) [88].
Axinohydantoins are structurally related to HMD, but, in the former, the glycocyamidine ring is replaced by a hydantoin ring. While 22 displayed interesting micromolar inhibitory activity against a number of kinases (PKC, IC50 = 9 μM; GSK-3β, IC50 = 3 μM; CDK1/cyclin B, IC50 = 4 μM; CK1, IC50 = 4.5 μM; CDC5/p25, IC50 = 7 μM) [6,68,87], 24 inhibits, always in the micromolar range, only protein kinase C (IC50 = 22 μM). In addition, a slight activity was found on murine P388 lymphocytic leukemia for (E)-axinohydantoin (23) (ED50 of 18 μg/mL) [85].
The first total syntheses of 24 and 25 were reported by Horne et al. [89]. Recently our group accomplished the first synthesis of (Z)- and (E)-axinohydantoins (22) and (23), along with a second generation synthesis of 24 and 25 [90]. To this purpose, the chemistry already optimized for HMD synthesis [78] was successfully employed.
Aldisine (26) and 2-bromoaldisine (27), available in multigram scale, were coupled with the versatile intermediate 1-benzoyl-2-methylsulfanyl-1,5-dihydroimidazol-4-one (21) to afford intermediates 28 and 29, which were readily converted to the corresponding hydantoins 30 and 31 (Scheme 5).
Intermediates 28 and 29 are also potentially suitable for preparing new analogues via nucleophilic displacement of the methylthio group. The cleavage of the benzoyl protecting group and the slow double bond endo/exo isomerization sequentially occurred in the presence of NH2NH2·H2O, thus delivering debromoaxinohydantoins (82% overall yield, 24/25 ratio: 90/10) and axinohydantoins (67% overall yield, 22/23 ratio: 80/20), respectively [90] (Scheme 6).

3.3. Dibromophakellstatin

(−)-Dibromophakellstatin 32 is a tetracyclic monomeric pyrrole-imidazole alkaloid, isolated from the Indian Ocean sponge Phakellia mauritiana in 1997 by Pettit et al., that showed interesting cell growth inhibitory activity against a minipanel of human cancer cell lines [91]. Since then, several total syntheses of the racemic natural product have been reported and reviewed [3,7,8,10]. The approaches by Lindel [92,93], Feldman [94,95], Austin [96] and Chen [97] for the construction of the tetracyclic core of rac-dibromophakellstatin are summarized in Scheme 7.
The first total synthesis of (−)-dibromophakellstatin 32 was accomplished by the Lindel group [98], who exploited the enantioselective version of their three-component imidazolinone annulation on a tricyclic enamide with TsONHCOOEt [92,93] (Scheme 8). Hydroxyproline was chosen as source of stereogenic information and used for the synthesis of chiral enamide 33, where the TBS-protected hydroxy group, positioned in the preferred axial conformation, efficiently controlled the stereochemistry of the annulation, thus affording intermediate 34 as single diastereoisomer. The endgame to the natural product was put through by the reductive removal of hydroxy group after its conversion into alkylbromide 35 and treatment with SmI2 that, simultaneously, reduced the C-Br bond and deprotected imidazolone nitrogens to 36. Final bromination with NBS afforded (−)-dibromophakellstatin 32.
In late 2007, a careful investigation of the antitumor activity of dibromophakellstatin both as racemic mixture and as single enantiomers has been reported by Lindel [99]. Rac-dibromophakellstatin was tested on a panel of 36 human tumor cell lines and proved to be active on ovarian (IC50 = 0.60 μM), glioblastoma (0.93 μM), non-small cell lung (0.96 μM) and uterus (1.21 μM) cancer cell lines. When inhibitory activity against these cell lines was tested for single enantiomers, only (−)-32 showed antitumor effects.

3.4. Agelastatins

Four closely related compounds belong to this class of tetracyclic PIAs. Agelastatin A (37) and its brominated congener agelastatin B (38) were isolated in 1993 [20] from the marine sponge Agelas dendromorpha by Pietra and co-workers. They were fully characterized by using a combination of molecular modelling, NMR and exciton splitting [100]. Few years later two new metabolites, namely agelastatin C (39) and agelastatin D (40) were isolated from the extracts of the sponge Cymbastela sp. by Molinski and co-workers [101] (Figure 6).
These natural products display a densely functionalized tetracyclic core with four contiguous stereocenters, which is an enticing and synthetically challenging structural motif. Agelastatin A (37) is reported to exhibit significant biological activity [9]. After its recognition as cytotoxic agent towards KB cells at concentration below 1 μg/mL [20], Pietra and Pettit research groups showed a powerful activity of 37 against a wide range of cancer cell lines such as human KB nasopharyngeal cancer cells, L1210 murine tumor cell line, RT112/84 bladder carcinoma cells, SK-MEL-5 melanoma cells, HCT-116 colon carcinoma cells, and MDA-MB-435s breast cancer cells [37,68,102]. Comparative studies showed that agelastatin A inhibited tumor cell growth from 1.5 to 16 times more potently than cisplatin, particularly, against human bladder, skin, colon, and breast carcinomas [103].
Very recently, agelastatin A (37) was demonstrated to be very effective in down-regulating the expression of β-catenin and in up-regulating Tcf-4, an inhibitor of osteopontin (OPN) at the cellular level. These two effects result in repression of OPN and inhibition of OPN-mediated malignant cell invasion, adhesion, and colony formation in vitro [104]. Longley also highlighted that agelastatin A’s ability in inhibiting β-catenin, which also controls transcription from the multidrug resistance 1 gene [105], could be helpful in reducing drug resistance issues, possibly both as single agent as well as in combination therapy. Together with its cytotoxic activity, agelastatin A was also envisioned as inhibitor of glycogen synthase kinase-3 β (GSK-3β), an enzyme responsible for the neurofibrillary tangles typically found in Alzheimer’s disease, and as a mimetic of insulin [106].
The impressive biological activity, together with its scarce availability, prompted many synthetic chemists to engage in the total synthesis of 37. To date, fourteen total syntheses have been achieved, each presenting different strategies to assemble the tetracyclic core of agelastatin A [11,107111].
In analogy to the previously published papers, the most recently reported syntheses of 37 show very different and elegant retrosynthetic analyses which represent a clear example of the creativity in the “art of total synthesis” [112]. The key structures involved in the achievement of agelastatin A synthesis are represented in Figure 7.
Trost and Dong applied a metal-catalyzed asymmetric allylic alkylation (AAA) [113] to the synthesis of 37 by using pyrroles and N-alkoxyamides (hydroxamic esters) as nucleophiles [114,115]. Key intermediate 43 was obtained using an AAA between bisallylic carbonate 41 and the bifunctional nucleophile 42. The challenging task, aimed at chemoselectively differentiating the two nucleophilic nitrogens in 42, successfully allowed a tandem cyclization to obtain pyrrolopiperazinone 44 (Scheme 9).
The Kresze reaction was used to carry out an allylic amination on 44. Subsequent treatment of 45 with methyl isocyanate gave urea 46 (Scheme 10). Hydroboration followed by NaBO3-mediated peroxidation gave alcohol 47 which, after Dess-Martin periodinane (DMP) oxidation and protective group removal, afforded (−)-37.
Ichikawa and co-workers achieved the total synthesis of (−)-37 by using a strategy involving a [3.3] sigmatropic rearrangement of an allyl cyanate as the key step [116]. The synthesis started with an elegant transformation of L-arabitol 48 to obtain allyl carbamate 49. Subsequent dehydration afforded allyl cyanate 50, which rearranged to 51 with a [1,3] chirality transfer of the stereogenic center via a concerted six-membered transition state (Scheme 11).
Further manipulations gave compound 52, which was in turn subjected to ring-closing metathesis using first generation Grubb’s catalyst thus securing cyclopentene 53. Introduction of the carbamate functionality followed by its dehydration delivered a substrate prone to a subsequent [3.3] sigmatropic rearrangement which, after isocyanate trapping, gave the vicinal diamine 54 (Scheme 12). The total synthesis of (−)-37 was then completed in eight steps.
Yoshimitsu, Ino and Tanaka [117] reported the total synthesis of 37 starting from enantiomerically pure aminoalcohol 55 which was converted in the pivotal azidoformate 56 in five steps (Scheme 13). Vicinal dinitrogen functionalities were introduced through thermal aziridination of the π-bond followed by ring opening, thus obtaining azide 57. Lactamization proceeded smoothly after azide reduction and nitrile hydrolysis affording carbamate 58, which was opened using methylamine. The resulting alcohol was carefully oxidized using TPAP, and the derived ketone was trapped in situ by the vicinal urea nitrogen. This extremely concise synthesis was completed via pyrrole bromination (Scheme 13).
One year later the same research group proposed a second-generation approach affording a streamlined process to obtain agelastatin A (37) [118]. This synthesis is based on an iron halide-triggered radical aminohalogenation. Intermediate 59 was considered the most suitable substrate because of its restricted mobility, which might improve the stereochemical outcome of the reaction during the halogen transfer step. After extensive investigations, the authors reported that the best results were achieved by performing the reaction in ethanol with FeBr2 as radical initiator in the presence of bromide salts, such as LiBr or Bu4NBr. Azidoformate 59 was thus treated under the abovementioned conditions delivering bromide 60 in satisfactory yield, which was in turn reacted with NaH in DMF affording lactam 58. Agelastatin A (37) was finally obtained in further three steps as outlined below (Scheme 14).
Intramolecular olefin aziridination was used in 2009 by Wehn and Du Bois [119] to forge agelastatin A. In their synthesis, sulfamate 61, easily prepared starting from commercially available materials, was subjected to aziridination in the presence of dimeric RuII catalyst in order to obtain 62, which was then regioselectively opened to give oxathiazepane 63. Interestingly, the catalyst was reported to be very effective, allowing very low loading (0.06 mol%) and high turnover number (>1500) thus enabling an easy and inexpensive scale-up. Key polyamine intermediate 64 was secured from 63 by treatment with ethylpyrocarbonate and then with NaSePh (Scheme 15).
After construction of the central core, agelastatin A was obtained in seven steps. Racemic 37 was recently prepared by Dickson and Wardrop [120] using a synthetic route in which a trichloroacetamide group plays the simultaneous role of a protecting group, a pendant nucleophile assisting the cyclofunctionalization and the latent urea required for the imidazolinone ring construction. The key compound all cis-substituted cyclopentene 68 has been obtained starting from the imidate 65, which after heating in xylenes, gave, through Overman rearrangement, trichloroacetamide 66. Compound 67 was obtained upon treatment with N-bromoacetamide followed by DBU-mediated debromination. Exposure of dihydrooxazole 67 to p-toluenesulfonic acid gave key compound 68 (Scheme 16).
Advanced intermediate 69 was easily obtained from 68 by converting the hydroxy group into the corresponding phthalimide under Mitsunobu conditions followed by installation of the urea moiety through displacement of the trichloroacetamide group. Tricycle 70 was forged by hydrazine-mediated phthalimide removal, coupling with 2-pyrrole carboxylic acid, acetate ester methanolysis, oxidation and base-mediated intramolecular cyclization. This synthesis was completed by removing the benzyl group with simultaneous imidazolidinone ring formation. Regioselective pyrrole bromination afforded (±)-37 (Scheme 17).
Chida and co-workers [121] envisioned diaminocyclopentene 74 as key intermediate for their agelastatin A synthesis. In order to obtain 74, bis-trichloroimidate 71, prepared in seven steps from commercially available d-tartaric acid, was subjected to a sequential Overman rearrangement. Allylic sulfide 72 thus obtained was oxidized to sulfoxide and, in the presence of P(OMe)3, underwent the Mislow-Evans rearrangement to diolefin 73. Grubbs’ catalyst provided smooth access to 74, which was finally converted into oxazoline 75 (Scheme 18).
Removal of the trichloroacetyl group in 75 with DIBAL, condensation of the resulting amine with 2-bromopyrrol-5-yl carboxylic acid, followed by hydrolysis of oxazoline and THP protection of the secondary alcohol afforded 76. In order to carry out the aza-Michael addition to construct the piperazinone ring, intermediate 76 was converted into protected N-methylurea 77 by treatment with 2,4-dimethoxybenzylmethyl amine (MeNHDMB). Removal of THP and oxidation of the secondary alcohol gave α,β-unsaturated ketone 78 which, in turn, underwent the final aza-Michael addition. Targeted (−)-37 was isolated in satisfactorily yield after oxidative cleavage of DMB group (Scheme 19).

4. Acyclic Dimers

4.1. Nagelamide D

Nagelamide D (79) [122] has a connection between C-10 and C-15′ of its oroidin monomer units and was isolated as a racemate by Kobayashi’s group in 2003 from Okinawan marine sponges of the genus Agelas. Some antibacterial activity was reported against Micrococcus luteus (MIC, 4.17 μg/mL), Bacillus subtilis (MIC, 33.3 μg/mL) and Escherichia coli (MIC, 33.3 μg/mL). Nagelamide D (79) was synthesized by Lovely group [123] in 2009 according to the retrosynthetic pathway depicted in Scheme 20. The envisioned strategy foresees a cross-coupling reaction between imidazolyl fragment A and vinyl fragment B, both accessible from a common precursor, the protected diiodoimidazole 80 [124].
The two actual fragments 81 and 82 were coupled according to the Baldwin procedure [125] for fluoride-mediated Stille reaction, providing bis-vinylimidazole 83 in good yield after treatment with TBAF to complete the partial desilylation. The next step was a catalytic hydrogenation to saturate both double bonds (Scheme 21).
Diol 84 was then protected as bis tbutyl-dimethylsilylether 85 and then transformed into the bis azide 86, before desilylation of the hydroxy groups with TBAF (Scheme 22). At this point, the two bromopyrrole moieties were introduced by means of a double Mitsunobu reaction with dibromopyrrolohydantoin derivative 87, which completed the formation of the nagelamide D full skeleton. The pyrrolohydantoin rings were then hydrolyzed, followed by imidazole deprotection with methanolic HCl. Azides were finally reduced over Lindlar catalyst affording nagelamide D (79), which was isolated as its TFA salt.
The authors reported that 1H-NMR of synthetic nagelamide D did not match that of the naturally occurring material; moreover, they were unable to get original NMR data from Kobayashi in order to unravel this inconsistency. Lovely also mentioned [123] an unpublished biomimetic total synthesis of nagelamide D by Horne et al., whose spectroscopic data perfectly matched the ones from Lovely group. The question whether the assigned structure or Kobayashi’s NMR data are in error remains open (on the subject see also Usami [126]).

4.2. Sceptrin

Sceptrin (8) (Figure 8) was isolated in 1981 by Faulkner and Clardy [127] from Agelas sceptrum. It is a dimeric pyrrole imidazole alkaloid formally made up by two hymenidin (11) subunits. The biogenetic hypothesis derives sceptrin from hymenidin (11) via an enzyme-mediated [2+2]-cycloaddition [127].
After some unfruitful attempts to synthesize sceptrin from urocanic acid derivatives [128], Baran [129] and Birman [130] independently reported the synthesis of racemic sceptrin in 2004; two years later, the first enantioselective synthesis of (−)-sceptrin was published (Scheme 23) [131]. Main hallmarks [132] of this approach are:
  • minimal use of protecting groups (benzylamide proved to be crucial for a complete transfer of chirality);
  • application of an oxaquadricyclane rearrangement/fragmentation [133] in natural product synthesis to diastereoselectively access the cyclobutane core of sceptrin;
  • application of a new chemo- and regioselective halogenation method [134];
  • formation of 2-aminoimidazole in mild conditions [135] (these moieties were voluntarily introduced at a later stage of the synthesis because the earlier introduction of this step resulted in compounds intractability).
Sceptrin has useful biological properties, like antibacterial and antiviral [136], antihistaminic and antimuscarinic activity [137139]; besides, it is a natural inhibitor of somatostatin [140]. Recently, Rodriguez and his group, through bidirectional affinity experiments, identified sceptrin as being able to bind to MreB [141], a cell wall regulator, and thus a validated antibiotic target [142]. When sceptrin interacts with MreB, cell wall disruption was observed.

5. Cyclic Dimers

5.1. Ageliferin

Ageliferins (9, 88 and 89, Figure 9) are dimeric pyrrole-imidazole alkaloids that have been isolated from the sponge Agelas conifera [136, 143]. This family of natural products showed antimicrobial and antiviral activity [136] as well as actomyosin ATPase activation [144]. Ageliferins, like the majority of alkaloids originated by sponges of the genus Agelas, are feeding deterrents.
The chemical defence that sponges adopt against predatory reef fishes has been investigated and measured [42], revealing that ageliferins, together with their close relatives sceptrins, are responsible for deterrence in the sponge Agelas conifera. Biogenetically, ageliferin (9) was hypothesized to derive from hymenidin (11) via an enzyme-mediated [4+2]-cycloaddition that infers chirality to achiral precursors, as well as an enzyme-catalyzed [2+2]-cycloaddition generates sceptrin (8) [29] (Figure 10).
Since its isolation and identification, several synthetic efforts aiming at the synthesis of 9 were based on this biogenetic hypothesis [3]. In 2004 Baran and co-workers speculated about the extracts composition of Agelas conifera [145] (Figure 11), in which sceptrin was dramatically more abundant than ageliferins [26]. If the two families of alkaloids derived from the same linear precursor via two different cycloaddition pathways, ageliferins should be thermodynamically more abundant than sceptrins in the extract.
An alternative biogenetic pathway was then postulated involving a formal [1,3]-sigmatropic rearrangement of sceptrin followed by a double bond isomerisation [26, 132] (Figure 10). According to this hypothesis, the vinylcyclobutane of rac-sceptrin was efficiently converted into the cyclohexene core of rac-ageliferin under microwave irradiation and some speculations on the reaction mechanism have been reported [26]. Two years later, Baran and co-workers published the accomplishment of the total synthesis of (−)-sceptrin (8), whose subsequent microwave-mediated vinylcyclobutane rearrangement yielded the naturally occurring (−)-ageliferin (9) (40% yield along with unreacted sceptrin) [131]. The scale-up of the reaction and the prolonged heating resulted in the formation of epi-ageliferin, later christened nagelamide E (90) [122], which was synthesized for the first time [132, 146] (Scheme 24).
Among the mechanistic speculations originally reported [26], the hypothesis of a 6-endo-trig recombination and olefin isomerization of the diradical intermediate deriving from the radical scission of the cyclobutane ring, showed to be more consistent with the observed partial stereochemical erosion.
A different approach to the core skeleton of ageliferin, as well as other oroidin cyclic dimers, has been reported by Chen et al. in 2006, who exploited a regiocontrolled MnIII-mediated oxidative heterobicyclization of a β-ketoester for the construction of tricycle 91. The reaction proceeded through a 5-exo/6-endo radical cyclization pathway [147] (Scheme 25).
Hydrolysis of 91 revealed ageliferin core 92, which was oxidatively rearranged to massadine skeleton 93 despite epimerization at C15. Lactone 91 can be oxidized after removal of the TIPS protective group, generating the spiro-derivative 94 with opposite facial selectivity. Subsequent hydrolysis afforded intermediate 95, which bears the palau’amine spiro-skeleton, but opposite relative configurations at C2 and C15.
In mid-2009 an alternative approach has been described by Lovely [148], who exploited a thermal intramolecular Diels-Alder (IMDA) on enyne 96 for the construction of the intermediate 97, which could be converted to ageliferins core 98 or, in turn, rearranged under oxidative conditions in the presence of Davis’ oxaziridine (99) to the palau'amine nucleus 100 (Scheme 26).

5.2. Palau’amine

The hexacyclic bisguanidine palau'amine (101) was isolated in 1993 by Scheuer and co-workers [149] from the sponge Stylotella agminata. It showed cytotoxicity against some tumor cell lines as well as antibiotic and antifungal activity. The relative configuration initially assigned (101a) to the structure implies a cis junction of the azabicylo[3.3.0]octane moiety and a cis relationship between the chlorine atom and the aminomethyl chain (Figure 12).
Later, while reporting the isolation and structure elucidation of tetrabromostyloguanidine (102) (also named carteramine A), Matsunaga [150] and Köck [151] raised the question for a revision of the assigned structure of palau'amine, according to NMR data and computational experiments on related compounds. Finally, in 2007 Quinn et al. [152] reported the correct structure of palau'amine (101b), entailing an inversion of configuration at C12, C17 and C20 (Figure 12) resulting in a thermodynamically less obvious trans-fused azabicylo[3.3.0]octane moiety and with the chlorine atom being trans to the vicinal aminomethyl chain.
In 1998 Scheuer [22] proposed palau'amine as biogenetically arising from a Diels-Alder reaction between 11,12-dehydrophakellin (103) and 3-amino-1-(2-aminoimidazolyl)prop-1-ene, followed by a chloroperoxidase-catalyzed chlorination that initiates a 1,2-shift/ring contraction and water addition (Scheme 27).
The revision of the structure of 101 exerted a profound influence on the biogenetic hypothesis concerning dimeric PIAs (see Subsection 1.1 and Figure 13).
Since its isolation, efforts towards the total synthesis of palau'amine have been increasing [3]. Recently Baran et al. have reported the total synthesis of axinellamines [153] and massadines [154]. These achievements may represent the prelude for the completion of their own strategy toward palau'amine.
Lovely exploited an intramolecular Diels-Alder approach (IMDA) for the construction of the intermediate 97 (see Scheme 26) that, after stereoselective double bond reduction, was subjected to an oxidative rearrangement thus securing the spiro-fused system of palau'amine (100). To this purpose Davis' reagent (99) [148] delivered better results than its ancestor dimethyldioxirane [155].
Chen reported a regiocontrolled MnIII-mediated oxidative heterobicyclization of a β-ketoester yielding the spiro intermediate 95 after suitable modifications [147] (Scheme 25).
Romo succeeded in the synthesis of the trans-fused azabicyclo[3.3.0]octane core of palau'amine by exploiting a biomimetic chlorination and a concomitant 1,2 shift/ring contraction of 104 for the construction of cis-fused intermediate 105 [27,156,157].
Subsequent selective deprotection, followed by simultaneous ring cleavage/epimerization with sodium methoxide afforded the anti-substituted cyclopentyl ester 106. Further manipulations yielded trans-azabicyclo[3.3.0]octane 107 [158] (Scheme 28).
The tricyclic prolinol derivative 107 was envisioned to be a suitable substrate for the application of the oxidative annulation strategy that recently provided the first enantioselective synthesis of (+)-phakellin from prolinol by Romo’s group [159]. This approach would lead to the targeted palau'amine (101).
Overman’s approach foresees thiosemicarbazide annulation on a densely functionalized 4,5-dihydropyrrole-2-carboxylate 108 as the key step for the assembly of a triazatriquinane 109, precursor of the cis-fused tetracyclic skeleton of epi-palau'amine [160]. Evolution of intermediate 109 by means of a SmI2-mediated N-N bond reduction yielded 110.
The following insertion of a spiro glycocyamidine ring, a subsequent TBAF-promoted cyclization for the assembly of the ketopiperazine moiety and further manipulations, resulted in the synthesis of hexacyclic congeners 111 and 112 of epi-palau’amine, bearing a cis configuration at the azabicyclo[3.3.0]octane core [161] (Scheme 29).
Harran exploited a different approach to palau'amine following his biogenetic proposal which was based upon a spirocycloisomerization of tethered alkylidene glycocyamidines [23]. For this purpose, tetrahydropyridazine (113) has been acylated with acyl chloride 114 [160] and subsequently elaborated to intermediate 115, from which target monomer 116 was derived by mild thermolysis in the presence of HgCl2.
Treatment of 116 with (i-PrCp)2TiCl2 prior to KHMDS, followed by exposure to FeCl2(DMF)3FeCl4, generated 117 as mixture of meso and C2 isomers. Hydrosilylation of 117, performed on the C2 isomer, and reduction mediated by proazaphosphatrane 118 yielded the partially debrominated bis-alkylidene derivative 119 that underwent spirocyclization in the presence of t-BuOCl affording the spirocyclic core of palau'amine 120 [162] (Scheme 30).

5.3. Axinellamines

Like palau’amine (101), axinellamines (121124), massadines (125, 126) and stylissadines (2, 3) (Figure 13) are PIAs with a high degree of complexity and for this reason they are appealing targets for total synthesis.
Axinellamines (121124) were first isolated from Axinella sp. [163]. Their architecture is characterized by important stereogenicity (8 contiguous stereocenters) and a fully decorated cyclopentane ring. Moreover, axinellamines B-D (122124) display antibacterial activity against Helicobacter pylori, a bacterium implicated in pepticular and gastric cancer (minimum inhibitory concentration (MIC) for bactericidal action against H. pylori at 1000 μM) [163]. Several papers have been published reporting synthetic efforts toward the synthesis of axinellamines and some of them have already been reviewed [2,3,7,147,164166].
The key intermediate in the synthesis of axinellamines is the elaborated cyclopentane ring A (Figure 14), also common to palau’amine, massadine, styloguanidine (127, Figure 13) [167] and stylissadines. The first enantioselective synthesis toward an analogue of A, which exploited the desymmetrization of 128, was reported by Carreira et al. in 2000 [165].
Many approaches to this intermediate were envisioned and they can be classified into four main categories [30] (Figure 14): a) linear [23,147], b) ring contraction, [27,129,132,146,156,157,166, 168171], c) ring expansion (this approach still awaits experimental realization) [132] d) abiotic [160,165, 172174].
The first total synthesis of axinellamine A (121) and B (122) was completed by Baran et al. [153] in 2008 starting from 129 and using an extremely straightforward approach. Key step was an oxidation (by means of AgII complex 132, Scheme 32), on polyfunctionalized intermediate 131. Both regioselectivity and overoxidation control of this reaction proved to be very impressive [34,153]. Synthesis of key intermediate 131 required 17 steps with an overall yield of 1.3% (Scheme 31).
Starting from advanced intermediate 131, the synthesis of 121 and 122, as racemic mixture, was then completed in 6 steps and an overall yield of approximately 0.3% (Scheme 32).

5.4. Massadines

Starting from 130, Baran et al. synthesized also massadine (125) and massadine chloride (126), a precursor of the daunting stylissadines (Figure 13).
Massadine was first isolated in 2003 from the marine sponge Stylissa aff. Massa [34]. Like the axinellamines, it is a dimeric pyrrole-imidazole alkaloid. Its peculiarity is due to the presence of a hydroxy group at C14 that renders this compound unique among the dimeric PIAs (Figure 13). Massadine (125) is biologically active as inhibitor of geranylgeranyltransferase type 1 from Candida albicans with IC50 of 3.9 μM [34]. A postulated biosynthetic precursor of 125 is massadine chloride (126), first isolated from Stylissa caribica [28]. Massadine chloride possesses a chlorine atom at C14, as in axinellamines (121124) (C13), palau’amine (101) (C17) and tetrabromostyloguanidine (102) (C17) [151] (Figure 13).
Syntheses of these alkaloids proved soon to be challenging due to the presence of many functional groups leading to several failed approaches [154]. Finally, 125 and 126, together with their unnatural C3,C7 epimers succumbed to total synthesis as reported in Scheme 33[154].
The key step of the synthesis was again the silver(II)-mediated oxidation reaction already reported in the synthesis of axinellamines (see Scheme 32). An optimization of the reaction conditions was necessary for massadines synthesis and led to the finding that TFA accelerates the oxidation, thus providing a general method to chemoselectively oxidize unprotected guanidines. Also the axinellamines synthesis overall yield was improved, obtaining 133 and 134 (Scheme 32), in shorter reaction times and at room temperature. The subsequent treatment of 135 with cyanamide required controlled pH conditions giving 136 along with its hydroxy analogue 137 (Scheme 33). The same reaction sequence was performed on both 136 and 137 leading to massadine chloride (126) and massadine (125) respectively, although each one associated with the corresponding C3,C7-epimer. Both 126 and 3,7-epi-(126) can be converted to their hydroxy analogues, 125 and 3,7-epi-(125), in warm water, probably involving a nucleophilic substitution mechanism with retention of configuration via a massadine aziridine species [28].

6. Cyclic Tetramers


Stylissadines (2 and 3, Figure 1 and 13) are tetrameric members of PIAs. Structurally, they are ether-linked dimers of massadine and thus the largest and the most complex structures within the oroidin family of alkaloids discovered so far. Stylissadine A (2) is the formal condensation product of two molecules of massadine (125) and it has a C2 symmetry. Stylissadine B (3), on the contrary, does not have a C2 symmetry because the C-2’ stereocenter is inverted [175]. Both have biological activity (2: IC50 = 0.7 μM; 3: IC50 = 1.8 μM) as antagonists of the P2X7 receptor involved in inflammatory diseases, but their high molecular weight and structural complexity render them hard to develop as drugs [176]. Efforts to convert massadine chloride into stylissadines are underway in Baran’s group.

7. Others

Ageladine A

In 2003, Fusetani et al. isolated the fluorescent alkaloid ageladine A (138) from the sponge Agelas Nakamurai by a bioassay-guided extraction [177]. Ageladine A is reported to inhibit several matrix metalloproteinases (MMPs-1, -2, -8, -9, -12 and -13). As it has been demonstrated that 138 does not chelate zinc ion like all known MMP-inhibitors do, the natural product probably operates with a completely different mechanism of action. Ageladine A showed also antiangiogenic effects. Moreover it is the first isolated PIA containing a 2-aminoimidazolopyridine moiety.
In the same paper, Fusetani also hypothesized a possible biogenesis of ageladine A: amino acids proline and histidine evolve to dibromopyrrole carboxyaldehyde and histamine, respectively. They subsequently generate intermediate imine 139, which undergoes oxidative intramolecular cyclization to afford 138 (Figure 15).
Since its isolation, quite a few total syntheses have been reported and recently reviewed [7,8,10]. As shown in Figure 16, the first generation Weinreb approach toward 138 settled a 6π-1-azatriene electrocyclization as the key step [178,179], while a biomimetic synthesis was reported one year later by the same group exploiting a 6π-2-azatriene electrocyclization [180,181]. In the meantime Karuso et al. published an elegant, two-step, biomimetic synthesis of ageladine A starting from 2-aminohistamine and 4,5-dibromo-2-formylpyrrole and moving through a Pictet-Spengler-type condensation [182].
An evaluation of the MMP-12 inhibition efficiency of ageladine A and its analogues has been reported by Ando and co-workers [183], confirming that the two bromine atoms and the NH groups are essential for the biological activity. Moreover very recently it has been demonstrated that 138 is a reliable and stable fluorescent pH sensor. Because of its permeability it can be used for detection of intracellular pH changes [184].

8. Conclusions

Pyrrole-imidazole alkaloids (PIAs), a quite enlarged family of metabolites exclusively found in marine sponges, fascinate the scientific community for several reasons. Although the isolation of the first representatives of this family dates back to the ‘70s, new relatives continue to be unveiled, thus requiring a parallel fine-tuning in the speculations around their biogenesis and their ecological role in the sponges. Moreover, the quest to support hypotheses with experimental data, by increasing our knowledge in sponges’ biochemistry, proved to be encumbered by the difficulties in artificial sponge cell culturing. Challenges are also plentiful from a synthetic point of view. Architectural complexity, unusually high nitrogen content (N/C ≅ 1:2), structural revisions, unknown absolute stereochemistry are just some of the dreadful aspects one has to take into account while planning a total synthesis of these alkaloids. Those synthetic efforts however should not be considered just as simple intellectual divertissements: some PIAs are gifted with promising biological activities, and larger availability of these compounds is key in developing more accurate pharmacological profiles.

References and Notes

  1. Wan, Y; Hur, W; Cho, CY; Liu, Y; Adrian, FJ; Lozach, O; Bach, S; Mayer, T; Fabbro, D; Meijer, L; Gray, NS. Synthesis and target identification of hymenialdisine analogs. Chem Biol 2004, 11, 247–259. [Google Scholar]
  2. Hoffmann, H; Lindel, T. Synthesis of the pyrrole-imidazole alkaloids. Synthesis 2003, 1753–1783. [Google Scholar]
  3. Jacquot, DEN; Lindel, T. Challenge palau'amine: Current standings. Curr Org Chem 2005, 9, 1551–1565. [Google Scholar]
  4. Jin, Z. Muscarine, imidazole, oxazole, and thiazole alkaloids. Nat Prod Rep 2005, 22, 196–229. [Google Scholar]
  5. Jin, Z. Imidazole, oxazole and thiazole alkaloids. Nat Prod Rep 2006, 23, 464–496. [Google Scholar]
  6. Nakao, Y; Fusetani, N. Enzyme inhibitors from marine invertebrates. J Nat Prod 2007, 70, 689–710. [Google Scholar]
  7. Weinreb, SM. Some recent advances in the synthesis of polycyclic imidazole-containing marine natural products. Nat Prod Rep 2007, 24, 931–948. [Google Scholar]
  8. Morris, JC; Phillips, AJ. Marine natural products: Synthetic aspects. Nat Prod Rep 2009, 26, 245–265. [Google Scholar]
  9. Fattorusso, E; Taglialatela-Scafati, O. Modern Alkaloids, 1st ed; Wyley VCH Verlag GmbH & Co KgaA: Weinheim, Germany, 2008. [Google Scholar]
  10. Jin, Z. Muscarine, imidazole, oxazole and thiazole alkaloids. Nat Prod Rep 2009, 26, 382–445. [Google Scholar]
  11. Kitagawa, I; Kobayashi, M; Kitanaka, K; Kido, M; Kyogoku, Y. Marine natural products. XII. On the chemical constituents of the Okinawan marine sponge Hymeniacidon aldis. Chem Pharm Bull 1983, 31, 2321–2328. [Google Scholar]
  12. Braekman, JC; Daloze, D; Stoller, C; Van Soest, RWM. Chemotaxonomy of Agelas (Porifera: Demospongiae). Biochem Syst Ecol 1992, 20, 417–431. [Google Scholar]
  13. Richelle-Maurer, E; De Kluijver, MJ; Feio, S; Gaudencio, S; Gaspar, H; Gomez, R; Tavares, R; Van De Vyver, G; van Soest, RWM. Localization and ecological significance of oroidin and sceptrin in the Caribbean sponge Agelas conifera. Biochem Syst Ecol 2003, 31, 1073–1091. [Google Scholar]
  14. Andrade, P; Willoughby, R; Pomponi, SA; Kerr, RG. Biosynthetic studies of the alkaloid, stevensine, in a cell culture of the marine sponge Teichaxinella morchella. Tetrahedron Lett 1999, 40, 4775–4778. [Google Scholar]
  15. Assmann, M; Lichte, E; Van Soest, RWM; Köck, M. New bromopyrrole alkaloid from the marine sponge Agelas wiedenmeyeri. Org Lett 1999, 1, 455–457. [Google Scholar]
  16. Vergne, C; Boury-Esnault, N; Perez, T; Martin, M-T; Adeline, M-T; Dau, ETH; Al Mourabit, A. Verpacamides A-D, a sequence of C11N5 diketopiperazines relating cyclo(Pro-Pro) to cyclo(Pro-Arg), from the marine sponge Axinella vaceleti: Possible biogenetic precursors of pyrrole-2-aminoimidazole alkaloids. Org Lett 2006, 8, 2421–2424. [Google Scholar]
  17. Travert, N; Al Mourabit, A. A likely biogenetic gateway linking 2-aminoimidazolinone metabolites of sponges to proline: Spontaneous oxidative conversion of the pyrrole-proline-guanidine pseudo-peptide to dispacamide A. J Am Chem Soc 2004, 126, 10252–10253. [Google Scholar]
  18. Foley, LH; Büchi, G. Biomimetic synthesis of dibromophakellin. J Am Chem Soc 1982, 104, 1776–1777. [Google Scholar]
  19. Fedoreev, SA; Il'In, SG; Utkina, NK; Maksimov, OB; Reshetnyak, MV; Antipin, MY; Struchkov, YT. The structure of dibromoagelaspongin - A novel bromine-containing guanidine derivative from the marine sponge Agelas sp. Tetrahedron 1989, 45, 3487–3492. [Google Scholar]
  20. D'Ambrosio, M; Guerriero, A; Debitus, C; Ribes, O; Pusset, J; Leroy, S; Pietra, F. Agelastatin A, a new skeleton cytotoxic alkaloid of the oroidin family. Isolation from the axinellid sponge Agelas dendromorpha of the Coral sea. J. Chem. Soc., Chem. Commun 1993, 1305–1306. [Google Scholar]
  21. Tsukamoto, S; Kato, H; Hirota, H; Fusetani, N. Mauritiamine, a new antifouling oroidin dimer from the marine sponge Agelas mauritiana. J Nat Prod 1996, 59, 501–503. [Google Scholar]
  22. Kinnel, RB; Gehrken, H-P; Swali, R; Skoropowski, G; Scheuer, PJ. Palau'amine and its congeners: A family of bioactive bisguanidines from the marine sponge. Stylotella aurantium J Org Chem 1998, 63, 3281–3286. [Google Scholar]
  23. Garrido-Hernandez, H; Nakadai, M; Vimolratana, M; Li, Q; Doundoulakis, T; Harran, PG. Spirocycloisomerization of tethered alkylidene glycocyamidines: Synthesis of a base template common to the palau'amine family of alkaloids. Angew. Chem., Int. Ed 2005, 44, 765–769. [Google Scholar]
  24. Faulkner, DJ; Andersen, RJ. Natural products chemistry of the marine environment. Sea 1974, 5, 679–714. [Google Scholar]
  25. Sharma, G; Magdoff-Fairchild, B. Natural products of marine sponges. 7. The constitution of weakly basic guanidine compounds, dibromophakellin and monobromophakellin. J Org Chem 1977, 42, 4118–4124. [Google Scholar]
  26. Baran, PS; O'Malley, DP; Zografos, AL. Natural product synthesis: Sceptrin as a potential biosynthetic precursor to complex pyrrole-imidazole alkaloids: The total synthesis of ageliferin. Angew. Chem., Int. Ed 2004, 43, 2674–2677. [Google Scholar]
  27. Wang, S; Dilley, AS; Poullennec, KG; Romo, D. Planned and unplanned halogenations in route to selected oroidin alkaloids. Tetrahedron 2006, 62, 7155–7161. [Google Scholar]
  28. Grube, A; Immel, S; Baran, PS; Köck, M. Massadine chloride: A biosynthetic precursor of massadine and stylissadine. Angew. Chem., Int. Ed 2007, 46, 6721–6724. [Google Scholar]
  29. Al Mourabit, A; Potier, P. Sponge's molecular diversity through the ambivalent reactivity of 2-aminoimidazole: A universal chemical pathway to the oroidin-based pyrrole-imidazole alkaloids and their palau'amine congeners. Eur J Org Chem 2001, 237–243. [Google Scholar]
  30. Köck, M; Grube, A; Seiple, IB; Baran, PS. The pursuit of palau'amine. Angew. Chem., Int. Ed 2007, 46, 6586–6594. [Google Scholar]
  31. Van Pee, K-H. Microbial biosynthesis of halometabolites. Arch Microbiol 2001, 175, 250–258. [Google Scholar]
  32. Butler, A; Carter-Franklin, JN. The role of vanadium bromoperoxidase in the biosynthesis of halogenated marine natural products. Nat Prod Rep 2004, 21, 180–188. [Google Scholar]
  33. Dong, C; Flecks, S; Unversucht, S; Haupt, C; van Pee, K-H; Naismith, JH. Tryptophan 7-halogenase (PrnA) structure suggests a mechanism for regioselective chlorination. Science 2005, 309, 2216–2219. [Google Scholar]
  34. Nishimura, S; Matsunaga, S; Shibazaki, M; Suzuki, K; Furihata, K; Van Soest, RWM; Fusetani, N. Massadine, a novel geranylgeranyltransferase type I inhibitor from the marine sponge Stylissa aff. massa. Org. Lett 2003, 5, 2255–2257. [Google Scholar]
  35. Jacquot, DEN; Mayer, P; Lindel, T. Chiroptical analysis of marine sponge alkaloids sharing the pyrrolopyrazinone core. Chem Eur J 2004, 10, 1141–1148. [Google Scholar]
  36. Fattorusso, E; Taglialatela-Scafati, O. Two novel pyrrole-imidazole alkaloids from the Mediterranean sponge. Agelas oroides Tetrahedron Lett 2000, 41, 9917–9922. [Google Scholar]
  37. D'Ambrosio, M; Guerriero, A; Ripamonti, M; Debitus, C; Waikedre, J; Pietra, F. The active centers of agelastatin A, a strongly cytotoxic alkaloid of the Coral Sea axinellid sponge Agelas dendromorpha, as determined by comparative bioassays with semisynthetic derivatives. Helv Chim Acta 1996, 79, 727–735. [Google Scholar]
  38. Chanas, B; Pawlik, JR; Lindel, T; Fenical, W. Chemical defense of the Caribbean sponge Agelas clathrodes (Schmidt). J Exp Mar Biol Ecol 1997, 208, 185–196. [Google Scholar]
  39. Wilson, DM; Puyana, M; Fenical, W; Pawlik, JR. Chemical defense of the Caribbean reef sponge Axinella corrugata against predatory fishes. J Chem Ecol 1999, 25, 2811–2823. [Google Scholar]
  40. Lindel, T; Hoffmann, H; Hochgurtel, M; Pawlik, JR. Structure-activity relationship of inhibition of fish feeding by sponge-derived and synthetic pyrrole-imidazole alkaloids. J Chem Ecol 2000, 26, 1477–1496. [Google Scholar]
  41. Assmann, M; Van Soest, RWM; Köck, M. New antifeedant bromopyrrole alkaloid from the Caribbean sponge Stylissa caribica. J Nat Prod 2001, 64, 1345–1347. [Google Scholar]
  42. Assmann, M; Lichte, E; Pawlik, JR; Köck, M. Chemical defenses of the Caribbean sponges Agelas wiedenmayeri and Agelas conifera. Mar Ecol Prog Ser 2000, 207, 255–262. [Google Scholar]
  43. Bickmeyer, U; Drechsler, C; Köck, M; Assmann, M. Brominated pyrrole alkaloids from marine Agelas sponges reduce depolarization-induced cellular calcium elevation. Toxicon 2004, 44, 45–51. [Google Scholar]
  44. Bickmeyer, U. Bromoageliferin and dibromoageliferin, secondary metabolites from the marine sponge Agelas conifera, inhibit voltage-operated, but not store-operated calcium entry in PC12 cells. Toxicon 2005, 45, 627–632. [Google Scholar]
  45. De Nanteuil, G; Ahond, A; Guilhem, J; Poupat, C; Tran Huu Dau, E; Potier, P; Pusset, M; Pusset, J; Laboute, P. Marine invertebrates from the New Caledonian lagoon. V. Isolation and identification of metabolites of a new species of sponge Pseudaxinyssa cantharella. Tetrahedron 1985, 41, 6019–6033. [Google Scholar]
  46. Fedoreev, SA; Utkina, NK; Il'In, SG; Reshetnyak, MV; Maksimov, OB. The structure of dibromoisophakellin from the marine sponge. Acanthella carteri Tetrahedron Lett 1986, 27, 3177–3180. [Google Scholar]
  47. Forenza, S; Minale, L; Riccio, R; Fattorusso, E. New bromopyrrole derivatives from the sponge Agelas oroides. J Chem Soc D 1971, 1129–1130. [Google Scholar]
  48. De Nanteuil, G; Ahond, A; Poupat, C; Thoison, O; Potier, P. Synthesis of oroidine. Bull Soc Chim Fr 1986, 813–816. [Google Scholar]
  49. Daninos-Zeghal, S; Al Mourabit, A; Ahond, A; Poupat, C; Potier, P. Synthesis of marine 2-aminoimidazole metabolites: Hymenidin, oroidin, and keramadine. Tetrahedron 1997, 53, 7605–7614. [Google Scholar]
  50. Berree, F; Girard-Le Bleis, P; Carboni, B. Synthesis of the marine sponge alkaloid oroidin and its analogues via Suzuki cross-coupling reactions. Tetrahedron Lett 2002, 43, 4935–4938. [Google Scholar]
  51. Olofson, A; Yakushijin, K; Horne, DA. Synthesis of C11N5 marine alkaloids oroidin, clathrodin, and dispacamides. Preparation and transformation of 2-amino-4,5-dialkoxy-4,5-dihydroimidazoline from 2-aminoimidazoles. J Org Chem 1998, 63, 1248–1253. [Google Scholar]
  52. Little, TL; Webber, SE. A simple and practical synthesis of 2-aminoimidazoles. J Org Chem 1994, 59, 7299–7305. [Google Scholar]
  53. Ando, N; Terashima, S. A novel synthesis of the 2-aminoimidazol-4-carbaldehyde derivatives, versatile synthetic intermediates for 2-aminoimidazole alkaloids. Synlett 2006, 2836–2840. [Google Scholar]
  54. Schroif-Gregoire, C; Travert, N; Zaparucha, A; Al Mourabit, A. Direct access to marine pyrrole-2-aminoimidazoles, oroidin, and derivatives, via new acyl-1,2-dihydropyridine intermediates. Org Lett 2006, 8, 2961–2964. [Google Scholar]
  55. Yamada, A; Kitamura, H; Yamaguchi, K; Fukuzawa, S; Kamijima, C; Yazawa, K; Kuramoto, M; Wang, G-Y-S; Fujitani, Y; Uemura, D. Development of chemical substances regulating biofilm formation. Bull Chem Soc Jpn 1997, 70, 3061–3069. [Google Scholar]
  56. Richards, JJ; Huigens, RW, III; Ballard, TE; Basso, A; Cavanagh, J; Melander, C. Inhibition and dispersion of proteobacterial biofilms. Chem Commun 2008, 1698–1700. [Google Scholar]
  57. Donlan, RM; Costerton, JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002, 15, 167–193. [Google Scholar]
  58. Musk, DJ, Jr; Hergenrother, PJ. Chemical countermeasures for the control of bacterial biofilms: Effective compounds and promising targets. Curr Med Chem 2006, 13, 2163–2177. [Google Scholar]
  59. Huigens, RW, III; Richards, JJ; Parise, G; Ballard, TE; Zeng, W; Deora, R; Melander, C. Inhibition of Pseudomonas aeruginosa biofilm formation with bromoageliferin analogues. J Am Chem Soc 2007, 129, 6966–6967. [Google Scholar]
  60. Richards, JJ; Ballard, TE; Melander, C. Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogs. Org Biomol Chem 2008, 6, 1356–1363. [Google Scholar]
  61. Ballard, TE; Richards, JJ; Wolfe, AL; Melander, C. Synthesis and antibiofilm activity of a second-generation reverse-amide oroidin library: A structure-activity relationship study. Chem Eur J 2008, 14, 10745–10761. [Google Scholar]
  62. Richards, JJ; Reed, CS; Melander, C. Effects of N-pyrrole substitution on the anti-biofilm activities of oroidin derivatives against Acinetobacter baumannii. Bioorg Med Chem Lett 2008, 18, 4325–4327. [Google Scholar]
  63. Richards, JJ; Reyes, S; Stowe, SD; Tucker, AT; Ballard, TE; Mathies, LD; Cavanagh, J; Melander, C. Amide isosteres of oroidin: Assessment of antibiofilm activity and C. elegans toxicity. J Med Chem 2009, 52, 4582–4585. [Google Scholar]
  64. Richards, JJ; Ballard, TE; Huigens, RW, III; Melander, C. Synthesis and screening of an oroidin library against Pseudomonas aeruginosa biofilms. ChemBioChem 2008, 9, 1267–1279. [Google Scholar]
  65. Cafieri, F; Fattorusso, E; Mangoni, A; Taglialatela-Scafati, O. Dispacamides, anti-histamine alkaloids from Caribbean Agelas sponges. Tetrahedron Lett 1996, 37, 3587–3590. [Google Scholar]
  66. Lindel, T; Hoffmann, H. Synthesis of dispacamide from the marine sponge Agelas dispar. Tetrahedron Lett 1997, 38, 8935–8938. [Google Scholar]
  67. Fresneda, PM; Molina, P; Sanz, MA. A convergent approach to midpacamide and dispacamide pyrrole-imidazole marine alkaloids. Tetrahedron Lett 2001, 42, 851–854. [Google Scholar]
  68. Meijer, L; Thunnissen, AMWH; White, AW; Garnier, M; Nikolic, M; Tsai, LH; Walter, J; Cleverley, KE; Salinas, PC; Wu, YZ; Biernat, J; Mandelkow, EM; Kim, SH; Pettit, GR. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000, 7, 51–63. [Google Scholar]
  69. Nguyen, TNT; Tepe, JJ. Preparation of hymenialdisine, analogues and their evaluation as kinase inhibitors. Curr Med Chem 2009, 16, 3122–3143. [Google Scholar]
  70. Sharma, GM; Buyer, JS; Pomerantz, MW. Characterization of a yellow compound isolated from the marine sponge Phakellia flabellata. J Chem Soc, Chem Commun 1980, 435–436. [Google Scholar]
  71. Cimino, G; De Rosa, S; De Stefano, S; Mazzarella, L; Puliti, R; Sodano, G. Isolation and X-ray crystal structure of a novel bromo compound from two marine sponges. Tetrahedron Lett 1982, 23, 767–768. [Google Scholar]
  72. Mattia, CA; Mazzarella, L; Puliti, R. 4-(2-Amino-4-oxo-2-imidazolin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one methanol solvate: A new bromo compound from the sponge Acanthella Aurantiaca. 1982, 2513–2515. [Google Scholar]
  73. Williams, DH; Faulkner, DJ. Isomers and tautomers of hymenialdisine and debromohymenialdisine. Nat Prod Lett 1996, 9, 57–64. [Google Scholar]
  74. Annoura, H; Tatsuoka, T. Total syntheses of hymenialdisine and debromohymenialdisine: Stereospecific construction of the 2-amino-4-oxo-2-imidazolin-5(Z)-disubstituted ylidene ring system. Tetrahedron Lett 1995, 36, 413–416. [Google Scholar]
  75. Xu, Y-Z; Yakushijin, K; Horne, DA. Synthesis of C11N5 marine sponge alkaloids: (±)-Hymenin, stevensine, hymenialdisine, and debromohymenialdisine. J Org Chem 1997, 62, 456–464. [Google Scholar]
  76. Sosa, ACB; Yakushijin, K; Horne, DA. A practical synthesis of (Z)-debromohymenialdisine. J Org Chem 2000, 65, 610–611. [Google Scholar]
  77. Portevin, B; Golsteyn, RM; Pierre, A; De Nanteuil, G. An expeditious multigram preparation of the marine protein kinase inhibitor debromohymenialdisine. Tetrahedron Lett 2003, 44, 9263–9265. [Google Scholar]
  78. Papeo, G; Posteri, H; Borghi, D; Varasi, M. A new glycocyamidine ring precursor: Syntheses of (Z)-hymenialdisine, (Z)-2-debromohymenialdisine, and (±)-endo-2-debromohymenialdisine. Org Lett 2005, 7, 5641–5644. [Google Scholar]
  79. Endo, M; Nakagawa, M; Hamamoto, Y; Ishihama, M. Pharmacologically active substances from southern pacific marine invertebrates. Pure Appl Chem 1986, 58, 387–394. [Google Scholar]
  80. He, Q; Chen, W; Qin, Y. Synthesis of 2-substituted endo-hymenialdisine derivatives. Tetrahedron Lett 2007, 48, 1899–1901. [Google Scholar]
  81. Chacun-Lefevre, L; Joseph, B; Merour, J-Y. Synthesis and reactivity of azepino[3,4-b]indol-5-yl trifluoromethanesulfonate. Tetrahedron 2000, 56, 4491–4499. [Google Scholar]
  82. Kaiser, HM; Zenz, I; Lo, WF; Spannenberg, A; Schroeder, K; Jiao, H; Goerdes, D; Beller, M; Tse, MK. Preparation of novel unsymmetrical bisindoles under solvent-free conditions: Synthesis, crystal structures, and mechanistic aspects. J Org Chem 2007, 72, 8847–8858. [Google Scholar]
  83. Mangu, N; Kaiser, HM; Kar, A; Spannenberg, A; Beller, M; Tse, MK. Synthesis of novel hymenialdisine analogues using solvent-free and silica gel-promoted ring opening of epoxides. Tetrahedron 2008, 64, 7171–7177. [Google Scholar]
  84. Parmentier, J-G; Portevin, B; Golsteyn, RM; Pierre, A; Hickman, J; Gloanec, P; De Nanteuil, G. Synthesis and CHK1 inhibitory potency of hymenialdisine analogues. Bioorg Med Chem Lett 2009, 19, 841–844. [Google Scholar]
  85. Pettit, GR; Herald, CL; Leet, JE; Gupta, R; Schaufelberger, DE; Bates, RB; Clewlow, PJ; Doubek, DL; Manfredi, KP; Rützler, K; Schmidt, JM; Tackett, LP; Ward, FB; Bruck, M; Camou, F. Antineoplastic agents. 168. Isolation and structure of axinohydantoin. Can J Chem 1990, 68, 1621–1624. [Google Scholar]
  86. Groszek, G; Kantoci, D; Pettit, GR. The isolation and structure elucidation of debromoaxinohydantoin. Liebigs Ann 1995, 715–716. [Google Scholar]
  87. Patil, AD; Freyer, AJ; Killmer, L; Hofmann, G; Johnson, RK. (Z)-Axinohydantoin and debromo-(Z)-axinohydantoin from the sponge Stylotella aurantium. Inhibitors of protein kinase C. Nat Prod Lett 1997, 9, 201–207. [Google Scholar]
  88. Inaba, K; Sato, H; Tsuda, M; Kobayashi, JI. Spongiacidins A-D, new bromopyrrole alkaloids from Hymeniacidon sponge. J Nat Prod 1998, 61, 693–695. [Google Scholar]
  89. Sosa, ACB; Yakushijin, K; Horne, DA. Synthesis of axinohydantoins. J Org Chem 2002, 67, 4498–4500. [Google Scholar]
  90. Tutino, F; Posteri, H; Borghi, D; Quartieri, F; Mongelli, N; Papeo, G. Stereoselective synthesis of (Z)-axino- and (Z)-debromoaxinohydantoin. Tetrahedron 2009, 65, 2372–2376. [Google Scholar]
  91. Boyd, MR; Pettit, GR; McNulty, J; Herald, DL; Doubek, DL; Chapuis, J-C; Schmidt, JM; Tackett, LP. Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian Ocean sponge. Phakellia mauritiana J Nat Prod 1997, 60, 180–183. [Google Scholar]
  92. Jacquot, DEN; Zoellinger, M; Lindel, T. Total synthesis of the marine natural product rac-dibromophakellstatin. Angew. Chem., Int. Ed 2005, 44, 2295–2298. [Google Scholar]
  93. Zoellinger, M; Mayer, P; Lindel, T. Total synthesis of the cytostatic marine natural product dibromophakellstatin via three-component imidazolidinone anellation. J Org Chem 2006, 71, 9431–9439. [Google Scholar]
  94. Feldman, KS; Skoumbourdis, AP. Extending Pummerer reaction chemistry. Synthesis of (±)-dibromophakellstatin by oxidative cyclization of an imidazole derivative. Org Lett 2005, 7, 929–931. [Google Scholar]
  95. Feldman, KS; Skoumbourdis, AP; Fodor, MD. Extending Pummerer reaction chemistry. Synthesis studies in the phakellin alkaloid area. J Org Chem 2007, 72, 8076–8086. [Google Scholar]
  96. Chung, R; Yu, E; Incarvito, CD; Austin, DJ. Hypervalent iodine-mediated vicinal syn diazidation: Application to the total synthesis of (±)-dibromophakellstatin. Org Lett 2004, 6, 3881–3884. [Google Scholar]
  97. Lu, J; Tan, X; Chen, C. Palladium-catalyzed direct functionalization of imidazolinone: Synthesis of dibromophakellstatin. J Am Chem Soc 2007, 129, 7768–7769. [Google Scholar]
  98. Zoellinger, M; Mayer, P; Lindel, T. Enantioselective total synthesis of (−)-dibromophakellstatin. Synlett 2007, 2756–2758. [Google Scholar]
  99. Zoellinger, M; Kelter, G; Fiebig, H-H; Lindel, T. Antitumor activity of the marine natural product dibromophakellstatin in vitro. Bioorg. Med. Chem. Lett 2007, 17, 346–349. [Google Scholar]
  100. D'Ambrosio, M; Guerriero, A; Chiasera, G; Pietra, F. Conformational preferences and absolute configuration of agelastatin A, a cytotoxic alkaloid of the axinellid sponge Agelas dendromorpha from the Coral Sea, via combined molecular modeling, NMR, and exciton splitting for diamide and hydroxyamide derivatives. Helv Chim Acta 1994, 77, 1895–1902. [Google Scholar]
  101. Hong, TW; Jimenez, DR; Molinski, TF. Agelastatins C and D, new pentacyclic bromopyrroles from the sponge Cymbastela sp., and potent arthropod toxicity of (−)-agelastatin A. J Nat Prod 1998, 61, 158–161. [Google Scholar]
  102. Pettit, GR; Ducki, S; Herald, DL; Doubek, DL; Schmidt, JM; Chapuis, J-C. Antineoplastic agents. 470. Absolute configuration of the marine sponge bromopyrrole agelastatin A. Oncol Res 2005, 15, 11–20. [Google Scholar]
  103. Hale, KJ; Domostoj, MM; El-Tanani, M; Campbell, FC; Mason, CK. Strategies and Tactics in Organic Synthesis; Harmata, M, Ed.; Academic Press: London, UK, 2005. [Google Scholar]
  104. Mason, CK; Mcfarlane, S; Johnston, PG; Crowe, P; Erwin, PJ; Domostoj, MM; Campbell, FC; Manaviazar, S; Hale, KJ; El-Tanani, M. Agelastatin A: A novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther 2008, 7, 548–558. [Google Scholar]
  105. Longley, DB; Johnston, PG. Molecular mechanisms of drug resistance. J Pathol 2005, 205, 275–292. [Google Scholar]
  106. Hale, KJ; Domostoj, MM; Tocher, DA; Irving, E; Scheinmann, F. Enantiospecific formal total synthesis of the tumor and GSK-3β inhibiting alkaloid, (−)-agelastatin A. Org Lett 2003, 5, 2927–2930. [Google Scholar]
  107. Stien, D; Anderson, GT; Chase, CE; Koh, Y-H; Weinreb, SM. Total synthesis of the antitumor marine sponge alkaloid agelastatin A. J Am Chem Soc 1999, 121, 9574–9579. [Google Scholar]
  108. Feldman, KS; Saunders, JC. Alkynyliodonium salts in organic synthesis. Application to the total synthesis of (−)-agelastatin A and (−)-agelastatin B. J Am Chem Soc 2002, 124, 9060–9061. [Google Scholar]
  109. Feldman, KS; Saunders, JC; Wrobleski, ML. Alkynyliodonium salts in organic synthesis. Development of a unified strategy for the syntheses of (−)-agelastatin A and (−)-agelastatin B. J Org Chem 2002, 67, 7096–7109. [Google Scholar]
  110. Domostoj, MM; Irving, E; Scheinmann, F; Hale, KJ. New total synthesis of the marine antitumor alkaloid (−)-agelastatin A. Org Lett 2004, 6, 2615–2618. [Google Scholar]
  111. Davis, FA; Deng, J. Asymmetric total synthesis of (−)-agelastatin A using sulfinimine (N-sulfinyl imine) derived methodologies. Org Lett 2005, 7, 621–623. [Google Scholar]
  112. Nicolaou, KC; Vourloumis, D; Winssinger, N; Baran, PS. The art and science of total synthesis at the dawn of the twenty-first century. Angew. Chem., Int. Ed 2000, 39, 44–122. [Google Scholar]
  113. Trost, BM; Crawley, ML. Asymmetric transition-metal-catalyzed allylic alkylations: Applications in total synthesis. Chem Rev 2003, 103, 2921–2943. [Google Scholar]
  114. Trost, BM; Dong, G. New class of nucleophiles for palladium-catalyzed asymmetric allylic alkylation. Total synthesis of agelastatin A. J Am Chem Soc 2006, 128, 6054–6055. [Google Scholar]
  115. Trost, BM; Dong, G. A stereodivergent strategy to both product enantiomers from the same enantiomer of a stereoinducing catalyst: Agelastatin A. Chem Eur J 2009, 15, 6910–6919. [Google Scholar]
  116. Ichikawa, Y; Yamaoka, T; Nakano, K; Kotsuki, H. Synthesis of (−)-agelastatin A by [3.3] sigmatropic rearrangement of allyl cyanate. Org Lett 2007, 9, 2989–2992. [Google Scholar]
  117. Yoshimitsu, T; Ino, T; Tanaka, T. Total synthesis of (−)-agelastatin A. Org Lett 2008, 10, 5457–5460. [Google Scholar]
  118. Yoshimitsu, T; Ino, T; Futamura, N; Kamon, T; Tanaka, T. Total synthesis of the β-catenin inhibitor, (−)-agelastatin A: A second-generation approach based on radical aminobromination. Org Lett 2009, 11, 3402–3405. [Google Scholar]
  119. Wehn, PM; Du Bois, J. A stereoselective synthesis of the bromopyrrole natural product (−)-agelastatin A. Angew. Chem., Int. Ed 2009, 48, 3802–3805. [Google Scholar]
  120. Dickson, DP; Wardrop, DJ. Total synthesis of (±)-agelastatin A, a potent inhibitor of osteopontin-mediated neoplastic transformations. Org Lett 2009, 11, 1341–1344. [Google Scholar]
  121. Hama, N; Matsuda, T; Sato, T; Chida, N. Total synthesis of (−)-agelastatin A: The application of a sequential sigmatropic rearrangement. Org Lett 2009, 11, 2687–2690. [Google Scholar]
  122. Endo, T; Tsuda, M; Okada, T; Mitsuhashi, S; Shima, H; Kikuchi, K; Mikami, Y; Fromont, J; Kobayashi, JI. Nagelamides A-H, new dimeric bromopyrrole alkaloids from marine sponge Agelas species. J Nat Prod 2004, 67, 1262–1267. [Google Scholar]
  123. Bhandari, MR; Sivappa, R; Lovely, CJ. Total synthesis of the putative structure of nagelamide D. Org Lett 2009, 11, 1535–1538. [Google Scholar]
  124. Lovely, CJ; Du, H; Sivappa, R; Bhandari, MR; He, Y; Dias, HVR. Preparation and Diels-Alder chemistry of 4-vinylimidazoles. J Org Chem 2007, 72, 3741–3749. [Google Scholar]
  125. Mee, SPH; Lee, V; Baldwin, JE. Significant enhancement of the Stille reaction with a new combination of reagents-copper(I) iodide with cesium fluoride. Chem Eur J 2005, 11, 3294–3308. [Google Scholar]
  126. Usami, Y. Recent synthetic studies leading to structural revisions of marine natural products. Mar Drugs 2009, 7, 314–330. [Google Scholar]
  127. Walker, RP; Faulkner, DJ; Van Engen, D; Clardy, J. Sceptrin, an antimicrobial agent from the sponge Agelas sceptrum. J Am Chem Soc 1981, 103, 6772–6773. [Google Scholar]
  128. D'Auria, M; Racioppi, R. Photochemical dimerization of esters of urocanic acid. J Photochem Photobiol 1998, 112, 145–148. [Google Scholar]
  129. Baran, PS; Zografos, AL; O'Malley, DP. Short total synthesis of (±)-sceptrin. J Am Chem Soc 2004, 126, 3726–3727. [Google Scholar]
  130. Birman, VB; Jiang, X-T. Synthesis of sceptrin alkaloids. Org Lett 2004, 6, 2369–2371. [Google Scholar]
  131. Baran, PS; Li, K; O'Malley, DP; Mitsos, C. Short, enantioselective total synthesis of sceptrin and ageliferin by programmed oxaquadricyclane fragmentation. Angew. Chem., Int. Ed 2006, 45, 249–252. [Google Scholar]
  132. O'Malley, DP; Li, K; Maue, M; Zografos, AL; Baran, PS. Total synthesis of dimeric pyrrole-imidazole alkaloids: Sceptrin, ageliferin, nagelamide E, oxysceptrin, nakamuric acid, and the axinellamine carbon skeleton. J Am Chem Soc 2007, 129, 4762–4775. [Google Scholar]
  133. Nelsen, SF; Calabrese, JC. Nucleophilic cleavage of quadricyclene-2,3-dicarboxylate derivatives by iodide. J Am Chem Soc 1973, 95, 8385–8389. [Google Scholar]
  134. Kajigaeshi, S; Kakinami, T; Moriwaki, M; Fujisaki, S; Maeno, K; Okamoto, T. Halogenation using quaternary ammonium polyhalides. Part X. α-Chlorination of aromatic acetyl derivatives with benzyltrimethylammonium dichloroiodate. Synthesis 1988, 545–546. [Google Scholar]
  135. Lancini, GC; Lazzari, E; Arioli, V; Bellani, P. Synthesis and relationship between structure and activity of 2-nitroimidazole derivatives. J Med Chem 1969, 12, 775–780. [Google Scholar]
  136. Keifer, PA; Schwartz, RE; Koker, MES; Hughes, RG, Jr; Rittschof, D; Rinehart, KL. Bioactive bromopyrrole metabolites from the Caribbean sponge Agelas conifera. J Org Chem 1991, 56, 2965–2975. [Google Scholar]
  137. Cafieri, F; Carnuccio, R; Fattorusso, E; Taglialatela-Scafati, O; Vallefuoco, T. Anti-histaminic activity of bromopyrrole alkaloids isolated from Caribbean Agelas sponges. Bioorg Med Chem Lett 1997, 7, 2283–2288. [Google Scholar]
  138. Shen, X; Perry, TL; Dunbar, CD; Kelly-Borges, M; Hamann, MT. Debromosceptrin, an alkaloid from the Caribbean sponge Agelas conifera. J Nat Prod 1998, 61, 1302–1303. [Google Scholar]
  139. Rosa, R; Silva, W; Escalona De Motta, G; Rodriguez, AD; Morales, JJ; Ortiz, M. Antimuscarinic activity of a family of C11N5 compounds isolated from Agelas sponges. Experientia 1992, 48, 885–887. [Google Scholar]
  140. Vassas, A; Bourdy, G; Paillard, JJ; Lavayre, J; Pais, M; Quirion, JC; Debitus, C. Naturally occurring somatostatin and vasoactive intestinal peptide inhibitors. Isolation of alkaloids from two marine sponges. Planta Med 1996, 62, 28–30. [Google Scholar]
  141. Rodriguez, AD; Lear, MJ; La Clair, JJ. Identification of the binding of sceptrin to MreB via a bidirectional affinity protocol. J Am Chem Soc 2008, 130, 7256–7258. [Google Scholar]
  142. Gitai, Z; Dye, NA; Reisenauer, A; Wachi, M; Shapiro, L. MreB actin-mediated segregation of a specific region of a bacterial chromosome. Cell 2005, 120, 329–341. [Google Scholar]
  143. Rinehart, KL. Biologically active marine natural products. Pure Appl Chem 1989, 61, 525–528. [Google Scholar]
  144. Kobayashi, J; Tsuda, M; Murayama, T; Nakamura, H; Ohizumi, Y; Ishibashi, M; Iwamura, M; Ohta, T; Nozoe, S. Ageliferins, potent actomyosin ATPase activators from the Okinawan marine sponge Agelas sp. Tetrahedron 1990, 46, 5579–5586. [Google Scholar]
  145. Assmann, M; Köck, M. Bromosceptrin, an alkaloid from the marine sponge Agelas conifera. Z Naturforsch, C J Biosci 2002, 57, 157–160. [Google Scholar]
  146. Northrop, BH; O'Malley, DP; Zografos, AL; Baran, PS; Houk, KN. Mechanism of the vinylcyclobutane rearrangement of sceptrin to ageliferin and nagelamide E. Angew. Chem., Int. Ed 2006, 45, 4126–4130. [Google Scholar]
  147. Tan, X; Chen, C. Regiocontrol in MnIII-mediated oxidative heterobicyclizations: Access to the core skeletons of oroidin dimers. Angew. Chem., Int. Ed 2006, 45, 4345–4348. [Google Scholar]
  148. Sivappa, R; Mukherjee, S; Dias, HVR; Lovely, CJ. Studies toward the total synthesis of the oroidin dimers. Org Biomol Chem 2009, 7, 3215–3218. [Google Scholar]
  149. Kinnel, RB; Gehrken, HP; Scheuer, PJ. Palau'amine: A cytotoxic and immunosuppressive hexacyclic bisguanidine antibiotic from the sponge Stylotella agminata. J Am Chem Soc 1993, 115, 3376–3377. [Google Scholar]
  150. Kobayashi, H; Kitamura, K; Nagai, K; Nakao, Y; Fusetani, N; Van Soest, RWM; Matsunaga, S. Carteramine A, an inhibitor of neutrophil chemotaxis, from the marine sponge Stylissa carteri. Tetrahedron Lett 2007, 48, 2127–2129. [Google Scholar]
  151. Grube, A; Köck, M. Structural assignment of tetrabromostyloguanidine: Does the relative configuration of the palau'amines need revision? Angew Chem, Int Ed 2007, 46, 2320–2324. [Google Scholar]
  152. Buchanan, MS; Carroll, AR; Quinn, RJ. Revised structure of palau'amine. Tetrahedron Lett 2007, 48, 4573–4574. [Google Scholar]
  153. O'Malley, DP; Yamaguchi, J; Young, IS; Seiple, IB; Baran, PS. Total synthesis of (±)-axinellamines A and B. Angew. Chem., Int. Ed 2008, 47, 3581–3583. [Google Scholar]
  154. Su, S; Seiple, IB; Young, IS; Baran, PS. Total syntheses of (±)-massadine and massadine chloride. J Am Chem Soc 2008, 130, 16490–16491. [Google Scholar]
  155. Lovely, CJ; Du, H; He, Y; Dias, HVR. Oxidative rearrangement of imidazoles with dimethyldioxirane. Org Lett 2004, 6, 735–738. [Google Scholar]
  156. Dilley, AS; Romo, D. Enantioselective strategy to the spirocyclic core of palau'amine and related bisguanidine marine alkaloids. Org Lett 2001, 3, 1535–1538. [Google Scholar]
  157. Dransfield, PJ; Dilley, AS; Wang, S; Romo, D. A unified synthetic strategy toward oroidin-derived alkaloids premised on a biosynthetic proposal. Tetrahedron 2006, 62, 5223–5247. [Google Scholar]
  158. Zancanella, MA; Romo, D. Facile synthesis of the trans-fused azabicyclo[3.3.0]octane core of the palau'amines and the tricyclic core of the axinellamines from a common intermediate. Org Lett 2008, 10, 3685–3688. [Google Scholar]
  159. Wang, S; Romo, D. Enantioselective synthesis of (+)-monobromophakellin and (+)-phakellin: A concise phakellin annulation strategy applicable to palau'amine. Angew. Chem., Int. Ed 2008, 47, 1284–1286. [Google Scholar]
  160. Katz, JD; Overman, LE. Studies towards the total synthesis of palau'amine. Formation of 4,5-dihydropyrrole-2-carboxylate intermediates by alkene-enamide ring-closing metathesis. Tetrahedron 2004, 60, 9559–9568. [Google Scholar]
  161. Lanman, BA; Overman, LE; Paulini, R; White, NS. On the structure of palau'amine: Evidence for the revised relative configuration from chemical synthesis. J Am Chem Soc 2007, 129, 12896–12900. [Google Scholar]
  162. Li, Q; Hurley, P; Ding, H; Roberts, AG; Akella, R; Harran, PG. Exploring symmetry-based logic for a synthesis of palau'amine. J Org Chem 2009, 74, 5909–5919. [Google Scholar]
  163. Urban, S; Leone, PDA; Carroll, AR; Fechner, GA; Smith, J; Hooper, JNA; Quinn, RJ. Axinellamines A-D, novel imidazo-azolo-imidazole alkaloids from the Australian marine sponge Axinella sp. J Org Chem 1999, 64, 731–735. [Google Scholar]
  164. Arndt, H-D; Riedrich, M. Synthesis of marine alkaloids from the oroidin family. Angew. Chem., Int. Ed 2008, 47, 4785–4788. [Google Scholar]
  165. Starr, JT; Koch, G; Carreira, EM. Enantioselective synthesis of the cyclopentyl core of the axinellamines. J Am Chem Soc 2000, 122, 8793–8794. [Google Scholar]
  166. Dransfield, PJ; Wang, S; Dilley, A; Romo, D. Highly regioselective Diels-Alder reactions toward oroidin alkaloids: Use of a tosylvinyl moiety as a nitrogen masking group with adjustable electronics. Org Lett 2005, 7, 1679–1682. [Google Scholar]
  167. Kato, T; Shizuri, Y; Izumida, H; Yokoyama, A; Endo, M. Styloguanidines, new chitinase inhibitors from the marine sponge Stylotella aurantium. Tetrahedron Lett 1995, 36, 2133–2136. [Google Scholar]
  168. Poullennec, KG; Romo, D. Enantioselective total synthesis of (+)-dibromophakellstatin. J Am Chem Soc 2003, 125, 6344–6345. [Google Scholar]
  169. Du, H; He, Y; Rasapalli, S; Lovely, CJ. New methods of imidazole functionalization - from imidazole to marine alkaloids. Synlett 2006, 965–992. [Google Scholar]
  170. Sivappa, R; Hernandez, NM; He, Y; Lovely, CJ. Studies toward the total synthesis of axinellamine and massadine. Org Lett 2007, 9, 3861–3864. [Google Scholar]
  171. Yamaguchi, J; Seiple, IB; Young, IS; O'Malley, DP; Maue, M; Baran, PS. Synthesis of 1,9-dideoxy-pre-axinellamine. Angew. Chem., Int. Ed 2008, 47, 3578–3580. [Google Scholar]
  172. Belanger, G; Hong, F-T; Overman, LE; Rogers, BN; Tellew, JE; Trenkle, WC. Stereocontrolled synthesis of triazacyclopenta[cd]pentalenes by intramolecular 1,3-dipolar cycloaddition reactions of azomethine imines. J Org Chem 2002, 67, 7880–7883. [Google Scholar]
  173. Lanman, BA; Overman, LE. Evaluation of strategies for the synthesis of the guanidine hemiaminal portion of palau'amine. Heterocycles 2006, 70, 557–570. [Google Scholar]
  174. König, SG; Miller, SM; Leonard, KA; Loewe, RS; Chen, BC; Austin, DJ. A Transient N-O-linked Pauson-Khand strategy for the synthesis of the deschloro carbocyclic core of the palau'amines and styloguanidines. Org Lett 2003, 5, 2203–2206. [Google Scholar]
  175. Grube, A; Köck, M. Stylissadines A and B: The first tetrameric pyrrole-imidazole alkaloids. Org Lett 2006, 8, 4675–4678. [Google Scholar]
  176. Buchanan, MS; Carroll, AR; Addepalli, R; Avery, VM; Hooper, JNA; Quinn, RJ. Natural products, stylissadines A and B, specific antagonists of the P2X7 receptor, an important inflammatory target. J Org Chem 2007, 72, 2309–2317. [Google Scholar]
  177. Fujita, M; Nakao, Y; Matsunaga, S; Seiki, M; Itoh, Y; Yamashita, J; Van Soest, RWM; Fusetani, N. Ageladine A: An antiangiogenic matrix metalloproteinase inhibitor from the marine sponge. Agelas nakamurai J Am Chem Soc 2003, 125, 15700–15701. [Google Scholar]
  178. Meketa, ML; Weinreb, SM. Total synthesis of ageladine A, an angiogenesis inhibitor from the marine sponge Agelas nakamurai. Org Lett 2006, 8, 1443–1446. [Google Scholar]
  179. Meketa, ML; Weinreb, SM; Nakao, Y; Fusetani, N. Application of a 6π-1-azatriene electrocyclization strategy to the total synthesis of the marine sponge metabolite ageladine A and biological evaluation of synthetic analogues. J Org Chem 2007, 72, 4892–4899. [Google Scholar]
  180. Meketa, ML; Weinreb, SM. A new total synthesis of the zinc matrixmetalloproteinase inhibitor ageladine A featuring a biogenetically patterned 6π-2-azatriene electrocyclization. Org Lett 2007, 9, 853–855. [Google Scholar]
  181. Meketa, ML; Weinreb, SM. A convergent total synthesis of the marine sponge alkaloid ageladine A via a strategic 6π-2-azatriene electrocyclization. Tetrahedron 2007, 63, 9112–9119. [Google Scholar]
  182. Shengule, SR; Karuso, P. Concise total synthesis of the marine natural product ageladine A. Org Lett 2006, 8, 4083–4084. [Google Scholar]
  183. Ando, N; Terashima, S. Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs. Bioorg Med Chem Lett 2007, 17, 4495–4499. [Google Scholar]
  184. Bickmeyer, U; Grube, A; Klings, K-W; Köck, M. Ageladine A, a pyrrole-imidazole alkaloid from marine sponges, is a pH sensitive membrane permeable dye. Biochem Biophys Res Commun 2008, 373, 419–422. [Google Scholar]
Figure 1. PIAs complexity extremes.
Figure 1. PIAs complexity extremes.
Marinedrugs 07 00705f1
Figure 2. PIAs biogenetic speculations.
Figure 2. PIAs biogenetic speculations.
Marinedrugs 07 00705f2
Figure 3. Examples of oroidin modification towards antibiofilm inhibitors.
Figure 3. Examples of oroidin modification towards antibiofilm inhibitors.
Marinedrugs 07 00705f3
Figure 4. Structures of HMD and DBH.
Figure 4. Structures of HMD and DBH.
Marinedrugs 07 00705f4
Figure 5. Axinohydantoins.
Figure 5. Axinohydantoins.
Marinedrugs 07 00705f5
Figure 6. Agelastatins.
Figure 6. Agelastatins.
Marinedrugs 07 00705f6
Figure 7. Different synthetic routes to achieve agelastatin A total synthesis.
Figure 7. Different synthetic routes to achieve agelastatin A total synthesis.
Marinedrugs 07 00705f7
Figure 8. Proposal for the biogenetic origin of sceptrin (8).
Figure 8. Proposal for the biogenetic origin of sceptrin (8).
Marinedrugs 07 00705f8
Figure 9. Ageliferins.
Figure 9. Ageliferins.
Marinedrugs 07 00705f9
Figure 10. Proposal for biogenetic origin for ageliferin (9).
Figure 10. Proposal for biogenetic origin for ageliferin (9).
Marinedrugs 07 00705f10
Figure 11. Extracts composition of Agelas conifera. Reproduced with permission from Verlag Z. Naturforsch. [145].
Figure 11. Extracts composition of Agelas conifera. Reproduced with permission from Verlag Z. Naturforsch. [145].
Marinedrugs 07 00705f11
Figure 12. Previously assigned (101a) and revised (101b) structure of palau’amine.
Figure 12. Previously assigned (101a) and revised (101b) structure of palau’amine.
Marinedrugs 07 00705f12
Figure 13. Structurally related PIAs cyclic dimers.
Figure 13. Structurally related PIAs cyclic dimers.
Marinedrugs 07 00705f13
Figure 14. Different approaches toward intermediate A.
Figure 14. Different approaches toward intermediate A.
Marinedrugs 07 00705f14
Figure 15. Proposed biogenesis for ageladine A (138).
Figure 15. Proposed biogenesis for ageladine A (138).
Marinedrugs 07 00705f15
Figure 16. Approaches to ageladine A (138).
Figure 16. Approaches to ageladine A (138).
Marinedrugs 07 00705f16
Scheme 1. Approach to oroidin and related compounds via intermediate 10.
Scheme 1. Approach to oroidin and related compounds via intermediate 10.
Marinedrugs 07 00705f17
Scheme 2. The Al Mourabit synthesis of oroidin.
Scheme 2. The Al Mourabit synthesis of oroidin.
Marinedrugs 07 00705f18
Scheme 3. Ando’s synthesis of dispacamide A.
Scheme 3. Ando’s synthesis of dispacamide A.
Marinedrugs 07 00705f19
Scheme 4. Synthetic approaches to (Z)-HMD (17) and (Z)-DBH (19).
Scheme 4. Synthetic approaches to (Z)-HMD (17) and (Z)-DBH (19).
Marinedrugs 07 00705f20
Scheme 5. Northern ring installation.
Scheme 5. Northern ring installation.
Marinedrugs 07 00705f21
Scheme 6. Benzoyl removal and double bond isomerization.
Scheme 6. Benzoyl removal and double bond isomerization.
Marinedrugs 07 00705f22
Scheme 7. Racemic approaches to (±)-dibromophakellstatin 32.
Scheme 7. Racemic approaches to (±)-dibromophakellstatin 32.
Marinedrugs 07 00705f23
Scheme 8. Enantioselective synthesis of (−)-32.
Scheme 8. Enantioselective synthesis of (−)-32.
Marinedrugs 07 00705f24
Scheme 9. Tandem Pd-AAA reported by Trost and Dong.
Scheme 9. Tandem Pd-AAA reported by Trost and Dong.
Marinedrugs 07 00705f25
Scheme 10. Completion of the Trost (−)-agelastatin A synthesis.
Scheme 10. Completion of the Trost (−)-agelastatin A synthesis.
Marinedrugs 07 00705f26
Scheme 11. Allyl cyanate [3.3] sigmatropic rearrangment involving a [1,3] chirality transfer.
Scheme 11. Allyl cyanate [3.3] sigmatropic rearrangment involving a [1,3] chirality transfer.
Marinedrugs 07 00705f27
Scheme 12. Access to key vicinal diamine 54.
Scheme 12. Access to key vicinal diamine 54.
Marinedrugs 07 00705f28
Scheme 13. Aziridination reaction used in agelastatin A synthesis.
Scheme 13. Aziridination reaction used in agelastatin A synthesis.
Marinedrugs 07 00705f29
Scheme 14. Yoshimitsu and Tanaka’s second-generation approach to (−)-37.
Scheme 14. Yoshimitsu and Tanaka’s second-generation approach to (−)-37.
Marinedrugs 07 00705f30
Scheme 15. Synthesis of selenide key intermediate 64.
Scheme 15. Synthesis of selenide key intermediate 64.
Marinedrugs 07 00705f31
Scheme 16. Synthesis of all cis-substituted cyclopentene 68.
Scheme 16. Synthesis of all cis-substituted cyclopentene 68.
Marinedrugs 07 00705f32
Scheme 17. Completion of (±)-37 synthesis according to Dickson and Wardrop.
Scheme 17. Completion of (±)-37 synthesis according to Dickson and Wardrop.
Marinedrugs 07 00705f33
Scheme 18. Synthesis of key compound 75.
Scheme 18. Synthesis of key compound 75.
Marinedrugs 07 00705f34
Scheme 19. Chida and co-workers completion of (−)-37 total synthesis.
Scheme 19. Chida and co-workers completion of (−)-37 total synthesis.
Marinedrugs 07 00705f35
Scheme 20. Retrosynthetic approach to Nagelamide D (79).
Scheme 20. Retrosynthetic approach to Nagelamide D (79).
Marinedrugs 07 00705f36
Scheme 21. Nagelamide D: Fragment Assembly and Reduction.
Scheme 21. Nagelamide D: Fragment Assembly and Reduction.
Marinedrugs 07 00705f37
Scheme 22. Completion of the synthesis of nagelamide D (79).
Scheme 22. Completion of the synthesis of nagelamide D (79).
Marinedrugs 07 00705f38
Scheme 23. Baran’s total synthesis of (−)-sceptrin (8).PLE = pig liver esterase, DMT-MM = 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride.
Scheme 23. Baran’s total synthesis of (−)-sceptrin (8).PLE = pig liver esterase, DMT-MM = 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride.
Marinedrugs 07 00705f39
Scheme 24. Enantioselective synthesis of (−)-ageliferin (9) and (−)-nagelamide E (90).
Scheme 24. Enantioselective synthesis of (−)-ageliferin (9) and (−)-nagelamide E (90).
Marinedrugs 07 00705f40
Scheme 25. Chen approach to oroidin cyclic dimers core.
Scheme 25. Chen approach to oroidin cyclic dimers core.
Marinedrugs 07 00705f41
Scheme 26. IMDA approach to ageliferins and palau’amine cores.
Scheme 26. IMDA approach to ageliferins and palau’amine cores.
Marinedrugs 07 00705f42
Scheme 27. Scheuer's proposal for biogenesis of palau'amine.
Scheme 27. Scheuer's proposal for biogenesis of palau'amine.
Marinedrugs 07 00705f43
Scheme 28. Romo’s approach to palau’amine core 107.
Scheme 28. Romo’s approach to palau’amine core 107.
Marinedrugs 07 00705f44
Scheme 29. Overman’s synthesis of congeners 111 and 112 of epi-palau’amine.
Scheme 29. Overman’s synthesis of congeners 111 and 112 of epi-palau’amine.
Marinedrugs 07 00705f45
Scheme 30. Harran's approach to palau'amine spirocyclic core 120.
Scheme 30. Harran's approach to palau'amine spirocyclic core 120.
Marinedrugs 07 00705f46
Scheme 31. Baran synthesis of key intermediate 131.
Scheme 31. Baran synthesis of key intermediate 131.
Marinedrugs 07 00705f47
Scheme 32. Completion of the axinellamine A (121) and B (122) total synthesis.* 77% (H, OH=β) and 48% (H, OH= α) after optimization: 132, H2O, TFA 10% (v:v), r.t155
Scheme 32. Completion of the axinellamine A (121) and B (122) total synthesis.* 77% (H, OH=β) and 48% (H, OH= α) after optimization: 132, H2O, TFA 10% (v:v), r.t155
Marinedrugs 07 00705f48
Scheme 33. Synthesis of 125 and 126.
Scheme 33. Synthesis of 125 and 126.
Marinedrugs 07 00705f49
Table 1. Kinase inhibition selectivity of 17.
Table 1. Kinase inhibition selectivity of 17.
EnzymeIC50 (nM)EnzymeIC50 (nM)

CDK1/cyclin B22Erk 1470
CDK2/cyclin A70Erk 22000
CDK2/cyclin E40c-raf>10,000
CDK3/cyclin E100MAPKK1200
CDK4/cyclin D1600GSK-3β10
CDK6/cyclin D2700CK27000
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top